Sélection de la langue

/ Government of Canada
Search

Sommaire du brevet 2997394 

Énoncé de désistement de responsabilité concernant l'information provenant de tiers

Une partie des informations de ce site Web a été fournie par des sources externes. Le gouvernement du Canada n'assume aucune responsabilité concernant la précision, l'actualité ou la fiabilité des informations fournies par les sources externes. Les utilisateurs qui désirent employer cette information devraient consulter directement la source des informations. Le contenu fourni par les sources externes n'est pas assujetti aux exigences sur les langues officielles, la protection des renseignements personnels et l'accessibilité.

Disponibilité de l'Abrégé et des Revendications

L'apparition de différences dans le texte et l'image des Revendications et de l'Abrégé dépend du moment auquel le document est publié. Les textes des Revendications et de l'Abrégé sont affichés :

  • lorsque la demande peut être examinée par le public;
  • lorsque le brevet est émis (délivrance).
(12) Brevet: (11) CA 2997394
(54) Titre français: NOUVEAU COMPOSE AMPHIPATHIQUE A BASE DE XYLENE ET SON UTILISATION
(54) Titre anglais: NOVEL XYLENE-BASED AMPHIPHILIC COMPOUND AND USE THEREOF
Statut: Accordé et délivré
Données bibliographiques
(51) Classification internationale des brevets (CIB):
  • C7H 15/00 (2006.01)
  • C7C 15/107 (2006.01)
  • C7H 3/04 (2006.01)
  • C7K 1/14 (2006.01)
  • G1N 1/28 (2006.01)
  • G1N 33/68 (2006.01)
(72) Inventeurs :
  • CHAE, PIL SEOK (Republique de Corée)
  • CHO, KYUNG HO (Republique de Corée)
(73) Titulaires :
  • INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS
(71) Demandeurs :
  • INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (Republique de Corée)
(74) Agent: PARLEE MCLAWS LLP
(74) Co-agent:
(45) Délivré: 2020-03-24
(86) Date de dépôt PCT: 2016-04-15
(87) Mise à la disponibilité du public: 2017-03-09
Requête d'examen: 2018-03-02
Licence disponible: S.O.
Cédé au domaine public: S.O.
(25) Langue des documents déposés: Anglais

Traité de coopération en matière de brevets (PCT): Oui
(86) Numéro de la demande PCT: PCT/KR2016/003929
(87) Numéro de publication internationale PCT: KR2016003929
(85) Entrée nationale: 2018-03-02

(30) Données de priorité de la demande:
Numéro de la demande Pays / territoire Date
10-2015-0124705 (Republique de Corée) 2015-09-03
10-2016-0045394 (Republique de Corée) 2016-04-14

Abrégés

Abrégé français

La présente invention concerne un composé amphipathique à base de xylène, un procédé pour le préparer, et un procédé pour extraire, solubiliser, stabiliser ou cristalliser des protéines membranaires au moyen dudit composé. Grâce à l'utilisation du composé à base de xylène selon la présente invention, des protéines membranaires peuvent être maintenues de manière stable dans une solution aqueuse pendant une longue période de temps et peuvent ainsi être utilisées dans l'analyse de leur fonction et leur structure. L'analyse de la structure et la fonction des protéines membranaires est l'un des champs qui reçoivent actuellement le plus d'attention en biologie et en chimie, et peut ainsi être appliquée à la recherche de structures protéiques, qui est étroitement liée à la mise au point de nouveaux médicaments.


Abrégé anglais


The present invention relates to a xylene-based amphiphilic compound, a method
for
manipulating a membrane protein using the same. Compounds of the invention,
for example, the
representative compound of formula 3:
(see above formula)
can be prepared from readily available starting materials. The amphiphilic
compounds can
manipulate membrane protein at relatively low concentrations compared to many
known
detergents. The compounds can be used to aid the isolation of membrane
proteins, for example,
to aid their solubilization and/or purification. The compounds can also be
used to aid the
functional and structural determination of membrane proteins, including their
stabilization and
crystallization.

Revendications

Note : Les revendications sont présentées dans la langue officielle dans laquelle elles ont été soumises.


WHAT IS CLAIMED IS:
1. A compound represented by Formula 1 below:
<IMG>
where the position of A2, relative to A1, is ortho, meta or para;
A1 and A2 are the same or different and each independently represented by
Formula 2 below;
<IMG>
R1 is a substituted or unsubstituted C3-C26 alkyl group, a substituted or
unsubstituted C3-C26 cycloalkyl group, or a substituted or unsubstituted C3-
C26 aryl
group;
X1 and X2 are each independently a saccharide linked by an oxygen atom;
and
the symbol * in Formula 2 may represent a part linked to the core structure
of Formula 1.
84

2. The compound of claim 1, wherein the saccharide is a monosaccharide
or a disaccharide.
3. The compound of claim 1, wherein the saccharide is glucose or maltose.
4. The compound of claim 1, wherein A1 and A2 are the same as each
other; R1 is a substituted or unsubstituted C3-C26 alkyl group; and X1 and X2
are
oxygen-linked maltoses.
5. The compound of claim 1, wherein A1 and A2 are the same as each
other; R1 is a substituted or unsubstituted C3-C26 alkyl group; and X1 and X2
are
oxygen-linked glucoses.
6. The compound of claim 1, wherein the compound is one of Formulas 3
to 20 below:
[Formula 3]

<IMG>
66

<IMG>
87

<IMG>
88

<IMG>
89

<IMG>

<IMG>
91

<IMG>
92

<IMG>
7. The compound of claim 1, wherein the compound is an amphiphilic
molecule for extracting, solubilizing, stabilizing, crystallizing or analyzing
a
membrane protein.
8. The compound of claim 1, wherein the compound has a critical
micelle concentration (CMC) of 0.1 to 1000µM in an aqueous solution.
9. A method for preparing the compound represented by Formula 1 below,
the method comprising:
1) introducing an alkyl group by performing monoalkylation on diethyl
malonate;
2) introducing a xylene linker by coupling the product of step 1) with
bis(bromomethyl)benzene;
93

3) reducing an ester functional group of the product of step 2) into an
alcohol
functional group;
4) introducing a protective group-attached saccharide by performing
glycosylation on the product of step 3); and
5) performing deprotection on the product of step 4):
<IMG>
where the position of A2, relative to A1, is ortho, meta or para;
A1 and A2 are the same or different and each independently represented by
Formula 2 below;
<IMG>
R1 is a substituted or unsubstituted C3-C26 alkyl group, a substituted or
unsubstituted C3-C26 cycloalkyl group, or a substituted or unsubstituted C3-
C26 aryl
group;
X1 and X2 are each independently a saccharide linked by an oxygen atom;
and
94

the symbol * in Formula 2 may represent a part linked to the core structure
of Formula 1.
10. A method for extracting, solubilizing, stabilizing, crystallizing or
analyzing a membrane protein, the method comprising:
treating a membrane protein with the compound represented by Formula 1
below in an aqueous solution:
<IMG>
where the position of A2, relative to A1, is ortho, meta or para;
A1 and A2 are the same or different and each independently represented by
Formula 2 below;
<IMG>
R1 is a substituted or unsubstituted C3-C26 alkyl group, a substituted or
unsubstituted C3-C26 cycloalkyl group, or a substituted or unsubstituted C3-
C26 aryl
group;

X1 and X2 are each independently a saccharide linked by an oxygen atom;
and
the symbol * in Formula 2 may represent a part linked to the core structure
of Formula 1 .
11. The method of claim 10, wherein the membrane protein is a boron
transporter (Bor1), a leucine transporter (LeuT), melibiose permease (MelB), a
human .beta.2 adrenergic receptor (.beta.2AR) or a combination of two or more
thereof
96

Description

Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.


CA 02997394 2018-03-02
NOVEL XYLENE-BASED AMPHIPHILIC COMPOUND AND USE
THEREOF
BACKGROUND
1. Field of the Invention
The present invention relates to a newly-developed xylene-based
amphiphilic compound, and a method for extracting, solubilizing, stabilizing,
crystallizing or analyzing a membrane protein using the same.
2. Discussion of Related Art
Membrane proteins are essential for biological systems. Since such bio-
macromolecules include hydrophilic and hydrophobic domains, an amphipathic
molecule is necessary to extract membrane proteins from a cell membrane, and
solubilize and stabilize the proteins in an aqueous solution.
For structural analysis of a membrane protein, good-quality membrane
protein crystals should be obtained, and to this end, structural stability of
a
membrane protein in an aqueous solution is required. While there are over a
hundred amphiphilic molecules that have been conventionally used in research
on
membrane proteins, only five of them have been widely used in research on the
.. structure of membrane proteins. These five amphiphilic molecules include n-
octyl-
P-D-glucopyranoside (OG), n-nonyl-p-D-glucopyranoside (NG), n-decyl-P-D-
maltopyranoside (DM), n-dodecyl-P-D-maltopyranoside (DDM), and
lauryldimethylamine-N-oxide (LDAO) (Non-Patent Document 1 and Non-Patent
Document 2). However, since many membrane proteins enclosed by these
1

CA 02997394 2018-03-02
molecules tend to be easily denatured and aggregated, thereby rapidly losing
their
function, there are considerable limitations to research on the function and
structure
of membrane proteins using such molecules. It is because conventional
molecules
have a simple chemical structure and thus do not exhibit various
characteristics.
Therefore, it is necessary to develop a novel amphiphile having novel and
excellent
characteristics due to a new structure.
Therefore, the inventors developed an amphiphilic compound which can be
used in research on membrane proteins, and thus completed the present
invention.
(Non-Patent Document 1) S. Newstead et al., Protein ScL 17 (2008) 466-472.
(Non-Patent Document 2) S. Newstead et al., MoL Membr. Biol. 25 (2008)
631-638.
SUMMARY OF THE INVENTION
The present invention is directed to providing a compound represented by
Formula 1.
The present invention is also directed to providing a composition for
extracting, s o I ubili zing, stabilizing, crystallizing or analyzing a
membrane protein,
which includes the above-mentioned compound.
The present invention is also directed to providing a method for preparing
the above-mentioned compound.
The present invention is also directed to providing a method for extracting,
solubilizing, stabilizing, crystallizing or analyzing a membrane protein using
the
above-mentioned compound.
2

CA 02997394 2018-03-02
In one aspect, the present invention provides a compound represented by
Formula I:
[Formula 1]
A1
-A2
In Formula 1,
the position of A2, relative to Al, may be ortho, meta or para;
Al and A2 may be the same or different, and may be each independently
represented by Formula 2 below;
[Formula 2]
_____________________________ X1
R1 __________________________ X2
R1 may be a substituted or unsubstituted C3-C26 alkyl group, a substituted or
unsubstituted C3-C26 cycloalkyl group, or a substituted or unsubstituted C3-
C26 aryl
group;
Xi and X2 may be each independently a saccharide linked by an oxygen
atom; and
the symbol * in Formula 2 may represent a part linked to the core structure
of Formula 1.
3

CA 02997394 2018-03-02
The term "saccharide" used herein refers to a carbohydrate compound which
is a relatively small molecule with a sweet taste when solubilized in water.
The
saccharide is classified into a monosaccharide, a disaccharide or a
polysaccharide
according to the number of molecules constituting a sugar.
The saccharide used in the embodiment may be a monosaccharide or a
disaccharide, and specifically, glucose or maltose, but the present invention
is not
limited thereto.
The saccharide may act as a hydrophilic group. The compound according
to one embodiment of the present invention has a smaller size when forming a
complex with a membrane protein by increasing a size of a hydrophilic group
and
minimizing an increase in length due to parallel linkage of four saccharides,
which
are hydrophilic groups. When the size of the complex of the compound and the
membrane protein is small, good-quality membrane protein crystals may be
obtained
(G. G. Prive, Methods 2007, 41, 388-397).
In addition, RI may act as a hydrophobic group. In the compound
according to one embodiment of the present invention, two alkyl groups may be
introduced as hydrophobic groups to optimize hydrophile-lipophile balance.
The compound according to an embodiment of the present invention may
have structurally rigid xylene, specifically, a p-xylene (p-dimethylbenzene),
m-
xylene (m-dimethylbenzene) or o-xylene (o-dimethylbenzene) linker. That is, as
two quaternary carbons are introduced into xylene terminals, flowability of
the entire
molecules may be highly limited, resulting in the promotion of the
crystallization of
the membrane protein.
4

CA 02997394 2018-03-02
Specifically, Al and A2 may be the same as each other; RI may be a
substituted or unsubstituted C3-C26 alkyl group; and Xi and X2 may be oxygen-
linked
maltoses. In one embodiment of the present invention, such compounds are named
"xylene-linked maltoside amphiphiles (XMAs)."
More specifically, the position of A2, relative to Al, may be para; Al and A2
may be the same as each other; RI may be a substituted or unsubstituted C3-C26
alkyl
group; and XI and X2 may be oxygen-linked maltoses. In one embodiment of the
present invention, such compounds are named "para-xylene-linked maltoside
amphiphiles (P-XMAs)."
In addition, the position of A2, relative to Ai, may be meta; Ai and A2 may
be the same as each other; RI may be a substituted or unsubstituted C3-C26
alkyl
group; and XI and X2 may be oxygen-linked maltoses. In one embodiment of the
present invention, such compounds were named "meta-xylene-linked maltoside
amphiphiles (M-XMAs)."
In addition, the position of A2, relative to Ai, may be ortho; Al and A2 may
be the same as each other; RI may be a substituted or unsubstituted C3-C26
alkyl
group; and X1 and X2 may be oxygen-linked maltoses. In one embodiment of the
present invention, such compounds are named "ortho-xylene-linked maltoside
amphiphiles (0-XMAs)."
In one embodiment of the present invention, a compound in which the
position of A2, relative to AI, may be para; Al and A2 may be the same as each
other;
RI may be a C8 alkyl group; and XI and X2 may be oxygen-linked maltoses is
named
"P-XMA-C8." Therefore, the compound may be a compound represented by
Formula 3 below:
5

CA 02997394 2018-03-02
[Formula 3]
OH
OH
HO
HO 0
H HO
HO OH
HO 0
HO OH 0
HO
HO OH
H HO HO
O
HO H 0 0
H '0.
In another embodiment of the present invention, a compound in which the
position of A2, relative to A', may be para; A' and A2 may be the same as each
other;
R1 may be a C9 alkyl group; and X' and X2 may be oxygen-linked maltoses is
named
"P-XMA-C9." Therefore, the compound may be a compound represented by
Formula 4 below:
[Formula 4]
OH
OH
HOM\
H 0
HO HO
0 FIVoor..\10H
HqO
0
HO
H-'047011\1 0
HO OH
HO OH
HO"--.VAtstAoti
HO H 0
OH
HO 0 0
In still another embodiment of the present invention, a compound in which
the position of A2, relative to Ai, may be para; Al and A2 may be the same as
each
6

CA 02997394 2018-03-02
other; RI may be a C10 alkyl group; and XI and X2 may be oxygen-linked
maltoses is
named "P-XMA-C 10." Therefore, the compound may be a compound represented
by Formula 5 below:
[Formula 5]
01-4
OH
HO OH 0
HO HO 0
o HO
0HTh
-
HO
HO OH
HO OH
\oti\?1,00
HO
HO HO
H
Sio OH Fio
In yet another embodiment of the present invention, a compound in which
the position of A2, relative to AI, may be para; AI and A2 may be the same as
each
other; RI may be a C11 alkyl group; and XI and X2 may be oxygen-linked
maltoses is
named "P-XMA-C 11." Therefore, the compound may be a compound represented
by Formula 6 below:
[Formula 6]
7

CA 02997394 2018-03-02
OH
0 OH
o
HO OH 04.4_
HO HO
HO OH Th
=
HO
HO OH 0
HO OH
HO
________________________ -
H -
HO HO
HO HO
HO
HCIHO HO
In yet another embodiment of the present invention, a compound in which
the position of A2, relative to A1, may be para; Al and A2 may be the same as
each
other; ft' may be a C12 alkyl group; and XI and X2 may be oxygen-linked
maltoses is
named "P-XMA-C12." Therefore, the compound may be a compound represented
by Formula 7 below:
[Formula 7]
OH
..)
HO \\
HO OH 44)..\__
HO HO
O OH
HO 0
CH)70 O
OH
HO
HO OH
0
HO HO
HO HO
HO_Ho OH
HO
In yet another embodiment of the present invention, a compound in which
the position of A2, relative to Al, may be meta; Ai and A2 may be the same as
each
other; ft' may be a C11 alkyl group; and X1 and X2 may be oxygen-linked
maltoses is
8

CA 02997394 2018-03-02
named "M-XMA-C11." Therefore, the compound may be a compound represented
by Formula 8 below:
[Formula 8]
OH
OH
HO
HO
H
HO HO H
U 0
HO
H-0314. =
HO
OH
HO
HO H HO
HO 0
HO
HO HO
HO
In yet another embodiment of the present invention, a compound in which
the position of A2, relative to Al, may be meta; Al and A2 may be the same as
each
other; RI may be a Ci2 alkyl group; and XI and X2 may be oxygen-linked
maltoses is
named "M-XMA-C12." Therefore, the compound may be a compound represented
by Formula 9 below:
[Formula 9]
9

CA 02997394 2018-03-02
OH
OH
H0*---0,0 ,,\ \f)
HO
H
HO H0HO 0,
u 0 '
HO
H--036. %1>.1 = H
HO
OH OH
0
HOOlefts`O.Ct) --0
HO H HO H
HOHO H o HO
In yet another embodiment of the present invention, a compound in which
the position of A2, relative to Al, may be meta; Al and A2 may be the same as
each
other; R' may be a C14 alkyl group; and X1 and X2 may be oxygen-linked
maltoses is
named "M-XMA-C14." Therefore, the compound may be a compound represented
by Formula 10 below:
[Formula 10]
OH
õ......i...\ \op OH
HO
HO 0
H
HO
HO11(;4.--0N,
_
0 t
0 =
HO
-
OH OH
0 0
HOrgedt-0,10.0t.....
...",,
HO
ICL- CX/1-171
HOrOti- HO
HO
In yet another embodiment of the present invention, a compound in which
the position of A2, relative to Al, may be meta; Al and A2 may be the same as
each
other; RI may be a C16 alkyl group; and X1 and X2 may be oxygen-linked
maltoses is

CA 02997394 2018-03-02
named "M-XMA-C16." Therefore, the compound may be a compound represented
by Formula 11 below:
[Formula 11]
OH
HO
HO
HO
-4
H
HO HO
HO 0,
0
0 '
HO
HO H "S'101.7
HO
OH OH
HO OH Ho H
HO HO 0
HO 0
0 H
Ho OH
HO
In yet another embodiment of the present invention, a compound in which
the position of A2, relative to Al, may be meta; Al and A2 may be the same as
each
other; RI may be a C18 alkyl group; and XI and X2 may be oxygen-linked
maltoses is
named "M-XMA-C18." Therefore, the compound may be a compound represented
by Formula 12 below:
[Formula 12]
OH
...i0 OH
HO
HO 0
H
HO HO H
HO 0
0 '
HO
H-0)4.9.%7NOI H =
HO
OH OH
0
HO HO H
HO es
HO
HOHO HO
11

CA 02997394 2018-03-02
In yet another embodiment of the present invention, a compound in which
the position of A2, relative to Ai, may be ortho; Al and A2 may be the same as
each
other; le may be a Cji alkyl group; and Xi and X2 may be oxygen-linked
maltoses is
named "0-XMA-C11." Therefore, the compound may be a compound represented
by Formula 13 below:
[Formula 131
OH
o OH
HO
HO
HO 0
HO HO HO 0
HO
HO
HO
OH OH
ticro0o=
HO
HO 0
01.40
FV3HO
In yet another embodiment of the present invention, a compound in which
the position of A2, relative to AI, may be ortho; Ai and A2 may be the same as
each
other; RI may be a C12 alkyl group; and XI and X2 may be oxygen-linked
maltoses is
named "0-XMA-C12." Therefore, the compound may be a compound represented
by Formula 14 below:
[Formula 14]
12

CA 02997394 2018-03-02
OH
OH
HO
HO 0
HO HO 0
HO
0 7
HO H 0
HO
OH 14:y OH
root.õ10
H O
O 0 H0
H 0
HO OHO
HO
In yet another embodiment of the present invention, a compound in which
the position of A2, relative to AI, may be ortho; AI and A2 may be the same as
each
other; RI may be a Ci4 alkyl group; and Xi and X2 may be oxygen-linked
maltoses is
named "0-XMA-C14." Therefore, the compound may be a compound represented
by Formula 15 below:
[Formula 151
OH
HO
0 OH
HO 0
HO HO
HO,,,/,_7\,
itN0
HO
OH OH
0 =
H H0 4:40
HO 0
0
HO -H HO
HO
In yet another embodiment of the present invention, a compound in which
the position of A2, relative to Al, may be ortho; Ai and A2 may be the same as
each
other; RI may be a C16 alkyl group; and XI and X2 may be oxygen-linked
maltoses is
13

CA 02997394 2018-03-02
named "0-XMA-C16." Therefore, the compound may be a compound represented
by Formula 16 below:
[Formula 16]
OH
0 OH
HO
HO 0 0
HO
HO
HO OH
HO
OH OH
0
HO H 0
HO HO 0
0
HO".4t- HO
HO
In yet another embodiment of the present invention, a compound in which
the position of A2, relative to Al, may be ortho; Al and A2 may be the same as
each
other; RI may be a C18 alkyl group; and XI and X2 may be oxygen-linked
maltoses is
named "0-XMA-C18." Therefore, the compound may be a compound represented
by Formula 17 below:
[Formula 17]
OH
,) OH
HO
HO
HO HO 0
=
HO OH
HO
OH OH
"4.
0
Pi 0
HO
0
Hipiets. Hto
HO
14

CA 02997394 2018-03-02
In addition, Al and A2 may be the same as each other; RI may be a
substituted or unsubstituted C3-C26 alkyl group; and XI and X2 may be oxygen-
linked
glucoses. In an embodiment of the present invention, such compounds are named
"xylene-linked glucoside amphiphiles (XGAs)." More specifically, here, when
the
position of A2, relative to Al, is para, the compounds are named "para-xylene-
linked
glucoside amphiphiles (P-XGAs)," when the position of A2, relative to Al, is
meta,
the compounds are named "meta-xylene-linked glucoside amphiphiles (M-XGAs),"
and when the position of A2, relative to Al, is ortho, the compounds are named
"ortho-xylene-linked glucoside amphiphiles (0-XGAs)."
In one embodiment of the present invention, a compound in which the
position of A2, relative to AI, may be para; Al and A2 may be the same as each
other;
RI may be a C4 alkyl group; and XI and X2 are oxygen-linked glucoses is named
"P-
XGA-C4." Therefore, the compound may be a compound represented by Formula
18 below:
[Formula 18]
OH
1-NO---,.0
HO...\____
0¨,
HO OH ¨
=
0
HO
HO
OH
OH
HO
0 0
HO
HO

CA 02997394 2018-03-02
In another embodiment of the present invention, a compound in which the
position of A2, relative to Al, may be para; Al and A2 may be the same as each
other;
RI may be a C5 alkyl group; and X1 and X2 are oxygen-linked glucoses is named
"P-
XGA-05." Therefore, the compound may be a compound represented by Formula
19 below:
[Formula 19]
OH
HO - _________ Ame,=:---4..\,..._
H 0
0 ---.,
-
7
HO
ii' 1141. No 0 H
0 H
H 0
OH
HO
0 0
HO
HO
In still another embodiment of the present invention, a compound in which
the position of A2, relative to Al, may be para; Al and A2 may be the same as
each
other; R' may be a C6 alkyl group; and X' and X2 are oxygen-linked glucoses is
named "P-XGA-C6." Therefore, the compound may be a compound represented by
Formula 20 below:
[Formula 20]
16
_

CA 02997394 2018-03-02
OH
HO
HO OH
0
HO OH
OH
OH
HOH0 OH
The compound according to another embodiment of the present invention
may be an amphiphilic molecule for extracting, solubilizing, stabilizing,
crystallizing
or analyzing a membrane protein, but the present invention is not limited
thereto.
The term "amphiphilic molecule" used herein refers to a molecule having
both a hydrophobic group and a hydrophilic group in one molecule, and having
affinity for polar and non-polar solvents. Phospholipid molecules present in a
surfactant or a cell membrane have a hydrophilic group at one end and a
hydrophobic
group at the other end, have amphiphilicity and form micelles or liposomes in
an
aqueous solution. Since the amphiphilic molecules have a hydrophilic group,
which
is polar, but a non-polar group is present, thcy tend to be poorly soluble in
water.
However, when a concentration exceeds a limit concentration (critical micelle
concentration, CMC), hydrophobic groups are collected inside due to a
hydrophobic
interaction, a micelle in which hydrophilic groups are directed to the surface
is
produced, resulting in an increase in solubility in water.
17

CA 02997394 2018-03-02
While a method for measuring CMC is not particularly limited, a method
widely known in the art may be used, and the measurement may be performed by,
for
example, a fluorescence staining method using diphenylhexatriene (DPH).
A compound according to an exemplary embodiment of the present
invention may have a CMC in an aqueous solution of 0.1 )1A4 to 1000 gM, and
specifically, 0.1 )IM to 100 111µ4, more specifically, 0.1 I.LM to 50 1.tM,
further more
specifically, 0.1 )tM to 30 )11µ4, further more specifically, 0.5 tiM to 30
)i,M, and for
example, 0.1 )(M to 25 [t1µ4 or 0.5 )tM to 25 11M, but the present invention
is not
limited thereto.
As compared with DDM, which has been generally used in conventional
research on a membrane protein, having a CMC of 170 )(M, the XMAs of the
embodiment have very small CMC values. Therefore, since a micelle is easily
formed with a small amount of XMAs, the membrane protein may be effectively
studied and analyzed using a small amount of XMAs, confirming that XMAs are
superior to DDM.
Another aspect of the present invention provides a composition for
extracting, solubilizing, stabilizing, crystallizing or analyzing a membrane
protein
including the above-described compound.
The composition may be prepared in the form of a micelle, a liposome, an
emulsion or a nanoparticle, but the present invention is not limited thereto.
The micelle may have a radius of 2.0 nm to 4.5 nm, specifically, 2.0 nm to
4.4 nm, more specifically, 2.1 to 4.3 nm, and for example, 2.2 nm to 4.2 nm,
but the
present invention is not limited thereto.
18

CA 02997394 2018-03-02
A method for measuring the radius of a micelle is not particularly limited,
but a method well known in the art may be used, and for example, the
measurement
may be performed using a dynamic light scattering (DLS) experiment.
As compared with DDM having a radius of 3.4 nm, XMAs also have a
micelle with a similar size to that of DDM, and it can be confirmed that a
novel
molecule has a geometrical shape in an aqueous solution, which is similar to
that of
DDM.
The micelle, liposome, emulsion or nanoparticle may include a membrane
protein therein. That is, the membrane protein present inside the cell
membrane
may be extracted by being enclosed by the micelle, liposome, emulsion or
nanoparticle. Therefore, it is possible to extract, solubilize, stabilize,
crystalize or
analyze the membrane protein by the micelle.
The composition may further include a buffer that is helpful in extracting,
solubilizing, stabilizing, crystallizing or analyzing the membrane protein.
Still another aspect of the present invention provides a method for preparing
a compound represented by Formula 1 below, the method including steps I) to 5)
as
follows:
1) introducing an alkyl group by performing monoalkylation on diethyl
malonate;
2) introducing a xylene linker by coupling the product of step 1) with
bis(bromomethyl)benzene;
3) reducing an ester functional group of the product of step 2) into an
alcohol
functional group;
19

CA 02997394 2018-03-02
4) introducing a protective group-attached saccharide by performing
glycosylation on the product of step 3); and
5) performing deprotection on the product of step 4).
[Formula I]
A1
A2
In Formula I,
the position of A2, relative to A1, may be ortho, meta or polo;
Al and A2 may be the same or different, and may be each independently
represented by Formula 2 below;
[Formula 21
_____________________________ X1
R1
_____________________________ X2
RI may be a substituted or unsubstituted C3-C26 alkyl group, a substituted or
unsubstituted C3-C26 cycloalkyl group, or a substituted or unsubstituted C3-
C26 aryl
group;
XI and X2 may be each independently saccharides linked by an oxygen
atom; and

CA 02997394 2018-03-02
the symbol * in Formula 2 may represent a part linked to the core structure
of Formula 1.
The b is(bromomethyl)benzene in Step 2) may be p-
bis(bromomethy 1)benz,ene, m-bis(bromomethyl)benzene or
o-
bis(bromomethyl)benzene.
Specifically, Al and A2 may be the same as each other; RI may be a
substituted or unsubstituted C3-C26 alkyl group; and Xi and X2 may be oxygen-
linked
maltoses.
In addition, Ai and A2 may be the same as each other; le may be a
substituted or unsubstituted C3-C26 alkyl group; and XI and X2 may be oxygen-
linked
glucoses.
The compound may be a compound represented by any one of Formulas 3 to
according to an exemplary embodiment of the present invention, but the present
invention is not limited thereto.
15 In this embodiment,
the compound may be synthesized from diethyl
malonate, which can be easily obtained, by a simple method. Since the compound
can be easily synthesized according to the preparation method of the present
invention, it is possible to produce a large amount of the compound to study a
membrane protein.
20 In one embodiment of
the present invention, XMAs are prepared by
performing the following steps according to a synthesis scheme illustrated in
FIG. 1,
3 or 4:
1) Compound A is obtained by adding 1-bromoalkane, K2CO3 THF, and
DMF to diethyl malonate and performing monoalkylation.
21

CA 02997394 2018-03-02
2) Product B into which a xylene linker is introduced is obtained by adding
NaH, bis(bromomethyl)benzene [p-
bis(bromomethyl)benzene, m-
bis(bromomethyl)benzene or o-bis(bromomethyl)benzene], THF and DMF to
Compound A.
3) Compound C is obtained by adding LiAIH4 and THF to Product B to
reduce an ester functional group into an alcohol functional group.
4) Product D into which a protection group-attached saccharide is introduced
is obtained by adding perbenzoylated maltosylbromide, Ag0Tf and CH2C12 to
Product C and performing glycosylation.
5) Product E (XMAs) is obtained by adding Na0Me and Me0H to Product
D and performing deprotection.
In one embodiment of the present invention, P-XGA-C4 to P-XGA-C6 are
prepared by performing the following steps according to the synthesis scheme
illustrated in FIG. I:
I) Compound A is obtained by adding I-bromoalkane, K2CO3, THF and
DMF to diethyl malonate and performing monoalkylation.
2) Product B into which a xylene linker is introduced is obtained by adding
NaH, bis(bromomethyl)benzene [p-bis(bromomethyl)benzene], THF and DMF to
Compound A.
3) Compound C is obtained by adding LiA1H4 and THF to Product B to
reduce an ester functional group into an alcohol functional group.
4) Product D into which a protection group-attached saccharide is introduced
is obtained by adding perbenzoylated glucosylbromide, Ag0Tf, CH2Cl2 and 2,4,6-
collidine to Product C and performing glycosylation.
22

CA 02997394 2018-03-02
5) Product E (XMAs) is obtained by adding Na0Me and Me0H to Product
D and performing deprotection.
A yet another aspect of the present invention provides a method for
extracting, solubilizing, stabilizing, crystallizing or analyzing a membrane
protein.
Specifically, the present invention provides a method for extracting,
solubilizing,
stabilizing, crystallizing or analyzing a membrane protein, the method
including
treating a membrane protein with a compound represented by Formula 1 in an
aqueous solution:
[Formula 11
A2
In Formula 1,
the position of A2, relative to Ai, may be ortho, meta or para;
Ai and A2 may be the same or different, and may be each independently
represented by Formula 2 below;
[Formula 2]
XX1
R1 __________________________ X2
23

CA 02997394 2018-03-02
RI may be a substituted or unsubstituted C3-C26 alkyl group, a substituted or
unsubstituted C3-C26 cycloalkyl group, or a substituted or unsubstituted C3-
C26 aryl
group;
XI and X2 may be each independently saccharides linked by an oxygen
atom; and
the symbol * in Formula 2 may represent a part linked to the core structure
of Formula 1.
Specifically, AI and A2 may be the same as each other; RI may be a
substituted or unsubstituted C3-C26 alkyl group; and XI and X2 may be oxygen-
linked
maltoses.
In addition, Ai and A2 may be the same as each other; RI may be a
substituted or unsubstituted C3-C26 alkyl group; and XI and X2 may be oxygen-
linked
glucoses.
The compound may be a compound represented by any one of Formulas 3 to
20 according to an exemplary embodiment of the present invention, but the
present
invention is not limited thereto.
The term "membrane protein" used herein refers to the generic term for
proteins or glycoproteins introduced into a cell membrane lipid bi layer. It
is present
in various states, for example, passing through the entire layer of the cell
membrane,
on the surface of the cell membrane, or attached to the cell membrane.
Examples of
the membrane protein include a receptor such as an enzyme, a peptide hormone
or a
local hormone, a receptor carrier such as a sugar, an ion channel, and an
antigen for a
cell membrane, but the present invention is not limited thereto.
24

CA 02997394 2018-03-02
The membrane protein includes any protein or glycoprotein introduced into
the lipid bilayer of a cell membrane, and specifically, a boron transporter
(Bort), a
leucine transporter (LeuT), melibiose permease (MelB), a human f32 adrenergic
receptor (132AR) or a combination of two or more thereof, but the present
invention is
not limited thereto.
The term "extraction of a membrane protein" used herein refers to separation
of a membrane protein from a cell membrane.
The term "solubilization of a membrane protein" used herein refers to the
solubilization of a water-insoluble membrane protein in an aqueous solution to
be
solubilized in a micelle.
The term "stabilization of a membrane protein" used herein refers to the
stable conservation of a tertiary or quaternary structure without a change in
structure
and function of a membrane protein.
The term "crystallization of a membrane protein" refers to the formation of
.. crystals of a membrane protein in a solution.
The term "analyzation of a membrane protein" used herein refers to analysis
of the structure or function of a membrane protein. In the embodiment, the
analysis
of a membrane protein may be carried out by a known method, but the present
invention is not limited thereto. For example, the structure of a membrane
protein
may be analyzed by electron microscopy.
By using xylene-based compounds according to exemplary embodiments of
the present invention, compared to a conventional compound, a membrane protein
can be stably stored in an aqueous solution for a long time, and can be
subjected to
functional analysis and structural analysis.

CA 02997394 2018-03-02
Since the structural and functional analysis of a membrane protein is one of
the fields of highest interest in biology and chemistry, the compounds
according to
exemplary embodiments of the present invention can be applied in research on
protein structure that is closely related to development of a new drug.
Specifically, the compounds according to exemplary embodiments of the
present invention can form a high quality membrane protein crystal due to a
small
size when a complex with the membrane protein is formed, and have a xylene
linker
which is structurally rigid and two quaternary carbon atoms introduced at a
xylene
terminal, thereby greatly limiting the flowability of the total molecule, and
therefore
the crystallization of the membrane protein can be promoted.
In addition, since the compounds of the present invention can be synthesized
from a starting material that can be easily obtained by a simple method, the
compounds can be mass-produced for research on a membrane protein.
BRIEF DESCRIPTION OF THE DRAWINGS
The above and other objects, features and advantages of the present
invention will become more apparent to those of ordinary skill in the art by
describing in detail exemplary embodiments thereof with reference to the
accompanying drawings, in which:
FIG. 1 is a diagram illustrating a synthesis scheme of P-XMAs and P-XGAs
according to Example I of the present invention;
FIG. 2 is a diagram illustrating chemical structures of P-XMAs and P-XGAs
according to examples of the present invention;
26

CA 02997394 2018-03-02
FIG. 3 is a diagram illustrating a synthesis scheme of M-XMAs according to
Example 2 of the present invention;
FIG. 4 is a diagram illustrating a synthesis scheme of 0-XMAs according to
Example 2 of the present invention;
FIG. 5 is a diagram illustrating chemical structures of M-XMAs and 0-
XMAs according to examples of the present invention;
FIG. 6 shows the 1H NMR spectrum of P-XMA-C8;
FIG. 7 shows the 13C NMR spectrum of P-XMA-C8;
FIG. 8 shows the 11=1 NMR spectrum of P-XMA-C9;
FIG. 9 shows the 13C NMR spectrum of P-XMA-C9;
FIG. 10 shows the 11-I NMR spectrum of P-XMA-C 10;
FIG. 11 shows the 13C NMR spectrum of P-XMA-C10;
FIG. 12 shows the 1H NMR spectrum of P-XMA-C 1 1;
FIG. 13 shows the 13C NMR spectrum of P-XMA-C11;
FIG. 14 shows the 1H NMR spectrum of P-XMA-C12;
FIG. 15 shows the 13C NMR spectrum of P-XMA-C12;
FIG. 16 shows the 1H NMR spectrum of M-XMA-Cll;
FIG. 17 shows the 13C NMR spectrum of M-XMA-C11;
FIG. 18 shows the 11-I NMR spectrum of M-XMA-C12;
FIG. 19 shows the 13C NMR spectrum of M-XMA-C12;
FIG. 20 shows the 1H NMR spectrum of M-XMA-C14;
FIG. 21 shows the 13C NMR spectrum of M-XMA-C14;
FIG. 22 shows the 1H NMR spectrum of M-XMA-C16;
FIG. 23 shows the 13C NMR spectrum of M-XMA-C16;
27

CA 02997394 2018-03-02
FIG. 24 shows the IFINMR spectrum of M-XMA-C18;
FIG. 25 shows the 13C NMR spectrum of M-XMA-C18;
FIG. 26 shows the 1H NMR spectrum of 0-XMA-C11;
FIG. 27 shows the 13C NMR spectrum of 0-XMA-C11;
FIG. 28 shows the IFINMR spectrum of 0-XMA-C12;
FIG. 29 shows the 13C NMR spectrum of 0-XMA-C12;
FIG. 30 shows the 1H NMR spectrum of 0-XMA-C14;
FIG. 31 shows the 13C NMR spectrum of 0-XMA-C14;
FIG. 32 shows the 11-INMR spectrum of 0-XMA-C16;
FIG. 33 shows the 13C NMR spectrum of 0-XMA-C16;
FIG. 34 shows the 1H NMR spectrum of 0-XMA-C18;
FIG. 35 shows the 13C NMR spectrum of 0-XMA-C18;
FIG. 36 is a set of graphs illustrating the size distribution of micelles
formed
by P-XMA-C8 (a), P-XMA-C9 (b), P-XMA-C10 (c), P-XMA-C11 (d), P-XMA-C12
(e), and DDM (f);
FIG. 37 is a set of graphs illustrating the size distribution of micelles
formed
by M-XMAs (a) and 0-XMAs (b). All amphiphilic compounds were used at a
concentration of 1.0 wt%;
FIG. 38 is a set of graphs illustrating the structural stability of a boron
transporter (Bor 1 ) in an aqueous solution by P-XMAs, measured using a CPM
assay:
(a) P-XMAs or DDM concentration: CMC + 0.04 wt%; and
(b) P-XMAs or DDM concentration: CMC + 0.2 wt%;
FIG. 39 is a set of graphs illustrating the structural stability of a leucine
transporter (LeuT) in an aqueous solution by XMAs (P-XMA-C11, M-XMAs, and
28

CA 02997394 2018-03-02
0-XMAs) or DDM. Protein stability is confirmed by measuring the ligand-binding
activity of a receptor through a scintillation proximity assay (SPA). In each
amphiphilic compound, LeuT is incubated for 12 days at room temperature, and
measured at regular intervals:
(a) XMAs or DDM concentration: CMC + 0.04 wt%; and
(b) XMAs or DDM concentration: CMC + 0.2 wt%;
FIG. 40 shows results of SDS-PAGE and western blotting, which show the
amount and structure of MelB protein extracted at four different temperatures
(0, 45,
55 and 65 C) using 1.5 wt% of P-XMAs or DDM;
FIG. 41 shows results of measuring the amount of MelB protein extracted at
four different temperatures (0, 45, 55 and 65 C) using 1.5 wt% of XMAs (P-
X1VIA-
Cl I and M-XMAs) or DDM:
(a) Results of SDS-PAGE and western blotting showing the amount and
structure of MelB protein; and
(b) Histogram of the total amount of proteins present in a membrane sample
(Memb) that is not treated with an amphiphilic compound by percentage;
FIG. 42 shows results of measuring the amount of MelB protein extracted at
four different temperatures (0, 45, 55 and 65 C) using 1.5 wt% of XMAs (P-XMA-
C11 and 0-XMAs) or DDM:
(a) Results of SDS-PAGE and western blotting showing the amount and
structure of MelB protein; and
(b) Histogram of the total amount of proteins present in a membrane sample
(Memb) that is not treated with an amphiphilic compound by percentage;
FIG. 43 shows results of measuring (32AR structural stability by P-XMAs:
29

CA 02997394 2018-03-02
(a) Fluorescence spectrum of mBBr-132AR solubilized in P-XMA-Cll and
DDM micelles according to the absence or presence of a full agonist
(isopreoterenol,
ISO), or a combination of ISO and G-protein;
(13) Fluorescence spectrum of mBBr-f12AR using P-XMA-C11, P-XMA-C12
or DDM at a concentration of CMC or less; and
(c) Result of measuring the ligand ([31-1]-DHA)-binding activity of 132AR
solubilized in DDM, P-XMA-CIl or P-XMA-C12;
FIG. 44 is a graph illustrating a result of measuring 02AR structural
stability
by DDM, P-XMA-C 11 or P-XMA-C12 in an unliganded form, an ISO-present state,
and ISO and G-protein-present state; and
FIG. 45 is a graph illustrating a result of measuring [32AR structural
stability
by XMAs, that is, the ligand ([31-11-DHA)-binding activity of 32AR solubilized
in
DDM, P-XMA-C II, M-XMAs (a) or 0-XMAs (b).
DETAILED DESCRIPTION OF EXEMPLARY EMBODIMENTS
Hereinafter, the present invention will be described in further detail with
reference to examples below. However, the following examples are merely
provided to illustrate the present invention, and the scope of the present
invention is
not limited thereto. It should be construed that the details which can be
easily
deduced from the detailed description and examples of the present invention by
those
of ordinary skill in the art belong to the scope of the present invention.
<Example 1> Methods for synthesizing P-XMAs and P-XGAs
The synthesis schemes for P-XMAs and P-XGAs are shown in FIG. 1.
Five types of para-xylene-linked maltoside amphiphiles (P-XMAs) and three
types of

CA 02997394 2018-03-02
para-xylene-linked glucoside amphiphiles (P-XGAs) were synthesized according
to
synthesis methods <1-1> to <1-5> below, and are shown in FIG. 2.
<1-1> Synthesis of Compound A
Diethyl malonate (5.0 equiv.) was solubilized in a solvent mixture of THF
(20 mL) and DMF (20 mL) at 1:1, and K2CO3 (5.0 equiv.) was slowly added in an
ice
bath at 0 C. The mixture was agitated until a sufficient amount of gas was
produced,
1-bromoalkane (1.0 equiv.) was added, and a reaction was performed for 6 hours
at
90 C. After the reaction, the product was extracted into an organic layer
using
diethyl ether, a 1M HCl aqueous solution (20 mL) and brine (100 mL). The
organic
layer was collected, water was removed using anhydrous Na2SO4, and the solvent
was evaporated using a rotary evaporator. Liquid Product A was obtained using
silica gel chromatography (Et0Ac/hexane).
<1-2> General synthesis procedure for introduction of xylene linker
(Step a; A-4i)
Compound A (2.4 equiv.) and NaH (3.0 equiv.) were solubilized in a solvent
mixture of THF (20 mL) and DMF (20 mL) at 1:1 in an ice bath at 0 C, and then
a,
a'-dibromo-p-xylene (1.0 equiv.) was added. The reaction was performed for 6
hours at room temperature. After the reaction, the product was extracted using
an
organic layer using diethyl ether (50 mL), a 1M HCl aqueous solution (20 mL)
and
brine (100 mL). The extracted organic layer was dehydrated using anhydrous
Na2SO4, and the solvent was removed using a rotary evaporator. Liquid Product
B
was obtained using silica gel chromatography (Et0Ac/hexane).
<1-3> General synthesis procedure for reduction of ester using lithium
aluminum hydride (LAH) (Step b;
31

CA 02997394 2018-03-02
Compound B was solubilized in THF (20 mL), and LiA1H4 (5.0 equiv.) was
slowly added in an ice bath at 0 C. The reaction mixture was reacted at room
temperature for one day. After the reaction, following slowly quenching with
Me0H, the resulting product was extracted into an organic layer using diethyl
ether
(2x30 mL), a 1M 1-ICI aqueous solution and brine. Water and a solvent were
removed from the extracted organic layer using anhydrous Na2SO4 and a rotary
evaporator, respectively. Solid Product C was obtained using silica gel
chromatography (Et0Ac/hexane).
<1-4> General synthesis procedure for glycosylation reaction (Step c;
C¨)D)
This procedure was carried out by a synthesis method proposed by P. R.
Ashton et al. (Chem. Eur. J. 1996, 2, 1115-1128.). An alcohol derivative,
Compound C, and Ag0Tf (5.0 equiv.) and 2,4,6-collidine (2.0 equiv.) were
solubilized in anhydrous CH2Cl2 (40 mL), and agitated at -45 C.
Perbenzoylated
maltosylbromide (5.0 equiv.) solubilized in anhydrous CH2C12 (40 mL) was added
to
the solution for 30 minutes. The reaction was performed at -45 C for 30
minutes,
and further performed for 90 minutes while a temperature was slowly increased
to
0 C. After the reaction, pyridine was added to the mixture, and filtered
through
Celite. The filtered liquid was washed using a 1M Na2S203 aqueous solution (40
mL) and an 0.1M HC1 aqueous solution (40 mL) and brine (2x40 mL). The organic
layer was dehydrated using anhydrous Na2SO4, and the solvent was distilled
using a
rotary evaporator. Solid Product D was obtained by purifying a residue using
silica
gel chromatography (Et0Ac/hexane).
32

<1-5> General synthesis procedure for deprotection reaction (Step d;
D¨>E)
This procedure was carried out by a synthesis method proposed by P. R.
Ashton et al. (Chem. Eur. J 1996, 2, 1115-1128.). 0-protected Compound D was
solubilized in Me0H, and then added until the final concentration of a 0.5M
methanolic
solution (Na0Me) became 0.05M. The reaction mixture was reacted at room
temperature
for 6 hours, and neutralized using an Amberlite"' IR-120 (H form) resin. The
resin was
removed from the reaction mixture using a glass filter, and a residue was
purified using
silica gel chromatography (Me0H/CH2C12). The residue was recrystallized using
CH2C12/Me0H/diethyl ether, thereby obtaining purer white solid Product E.
Product E
obtained thereby is a compound of the present invention, P-XMAs.
<Example 2> Synthesis of M-XMAs and 0-XMAs
The synthesis scheme of M-XMAs is shown in FIG. 3, and the synthesis
scheme of 0-XMAs is shown in FIG. 4. Five types of meta-xylene-linked
maltoside
amphiphiles (M-XMAs) and five types of ortho-xylene-linked maltoside
amphiphiles (0-
XMAs) were synthesized by synthesis methods <2-1> to <2-5> below, and are
shown in
FIG. 5.
<2-1> Synthesis of Compound A
Diethyl malonate (5.0 equiv.) was solubilized in a solvent mixture of
THF (15 mL) and DMF (30 mL) at 1:2, and K2CO3 (5.0 equiv.) was slowly added in
an ice
bath at 0 C. The mixture was agitated until a sufficient amount of gas was
produced, 1-
bromoalkane (1.0 equiv.) was added, and a reaction was performed for 6 hours
at 60 C.
After the reaction, the product was extracted into an organic layer
33
CA 2997394 2019-08-07

CA 02997394 2018-03-02
using diethyl ether, a 0.1M HCI aqueous solution (70 mL) and brine (100 mL).
The
organic layer was collected, water was removed using anhydrous Na2SO4, and the
solvent was evaporated using a rotary evaporator. Oily liquid Product A was
obtained using silica gel chromatography (Et0Ac/hexane).
<2-2> General synthesis procedure for introduction of xylene linker
(Step a; A-43)
Compound A (2.4 equiv.) and NaH (3.0 equiv.) were solubilized in a solvent
mixture of THF (10 mL) and DMF (20 mL) at 1:2 in an ice bath at 0 C, and then
m-
xylylene dibromide or o-xylylene dibromide (1.0 equiv.) was added. The
reaction
was performed for 6 hours at room temperature. After the reaction, the product
was
extracted into an organic layer using diethyl ether (50 mL), a 0.1M HCl
aqueous
solution (20 mL) and brine (100 mL). The extracted organic layer was
dehydrated
using anhydrous Na2SO4, and the solvent was removed using a rotary evaporator.
Oily liquid Product B was obtained using silica gel chromatography
(Et0Ac/hexane).
<2-3> General synthesis procedure for reduction of ester using lithium
aluminum hydride (LAI-I) (Step b; B¨*C)
Compound B (1.0 equiv.) was solubilized in THF (30 mL), and LiA1H4(5.0
equiv.) was slowly added in an ice bath at 0 C. The reaction mixture was
reacted
at room temperature for one day. After the reaction, following slowly
quenching
with Me0H, the resulting product was extracted into an organic layer using
diethyl
ether (2x30 mL), a 1M HC1 aqueous solution and brine. Water and a solvent were
removed from the extracted organic layer using anhydrous Na2SO4 and a rotary
evaporator, respectively. White solid Product C was obtained using silica gel
chromatography (Et0Ac/hexane).
34

CA 02997394 2018-03-02
<2-4> General synthesis procedure for glycosylation reaction (Step c;
C-4:)
This procedure was carried out by a synthesis method proposed by P. R.
Ashton et al. (Chem. Eur. J. 1996, 2, 1115-1128.). An alcohol derivative,
Compound C, and Ag0Tf (5.0 equiv.) and 2,4,6-collidine (2.0 equiv.) were
solubilized in anhydrous CH2C12 (40 mL), and agitated at -45 C.
Perbenzoylated
maltosylbromide (5.0 equiv.) solubilized in anhydrous CH2C12 (40 mL) was added
to
the solution for 30 minutes. The reaction was performed at -45 C for 30
minutes,
and further performed for 90 minutes while a temperature was slowly increased
to
0 C. After the reaction, pyridine was added to the mixture, and filtered
through
Celite. The filtered liquid was washed using a 1M Na2S203 aqueous solution (40
mL) and a 0.1M HCI aqueous solution (40 mL) and brine (2x40 mL). The organic
layer was dehydrated using anhydrous Na2SO4, and the solvent was distilled
using a
rotary evaporator. White solid Product D was obtained by purifying a residue
using
silica gel chromatography (Et0Ac/hexane).
<2-5> General synthesis procedure for deprotection reaction (Step d;
D¨>E)
This procedure was carried out by a synthesis method proposed by P. R.
Ashton et aL (Chem. Eur. J. 1996, 2, 1115-1128.). 0-protected Compound D was
solubilized in Me0H, and then added until the final concentration of a 0.5M
methanolic solution (Na0Me) became 0.05M. The reaction mixture was reacted at
room temperature for 6 hours, and neutralized using an Amberlite IR-120 (H+
form)
resin. The resin was removed from the reaction mixture using a glass filter,
and a
residue was purified using silica gel chromatography (Me0H/CH2C12). The
residue

CA 02997394 2018-03-02
was recrystallized using CH2C12/Me0H/diethyl ether, thereby obtaining purer
white
solid Product E. Product E obtained thereby is a compound of the present
invention,
M-XMAs or 0-XMAs.
<Preparation Example 1> Synthesis of P-XMA-C8
<1-1> Synthesis of diethyl 2-octylmalonate (1)
Diethyl 2-octylmalonate (1) was synthesized with a yield of 88% according
to the general procedure for the synthesis of Compound A of Example 1-1. 114
NMR (400MHz, CDC13): 6 4.24-4.15 (m, 4H), 3.31 (t, J = 7.6 Hz, 1H), 1.89-1.87
(m,
2H), 1.30-1.24 (m, 18H), 0.87 (t, J = 7.2 Hz, 3H); 13C NMR (100MHz, CDCI3): 6
169.9, 61.4, 52.3, 33.1, 29.8, 29.7, 29.4, 28.9, 27.5, 22.9, 14.3.
<1-2> Synthesis of tetraethyl 2,2'-(1,4-phenylenebis(methylene))bis(2-
octylmalonate) (6)
Tetraethyl 2,2'-(1,4-pheny I enebis(methy lene))bis(2-octy lmalonate) (6) was
synthesized with a yield of 84% according to the general procedure for the
introduction of a xylene linker of Example 1-2. 114 NMR (400MHz, CDC13): 6
6.95
(s, 4H), 4.22-4.09 (m, 8H), 3.17 (s, 4H), 1.75-1.73 (m, 4H), 1.26-1.20 (m,
36H), 0.88
(t, J = 7.2 Hz, 6H); '3C NMR (100MHz, CDC13): 6 171.6, 135.1, 129.9, 61.3,
58.9,
37.8, 32.0, 31.9, 29.9, 29.5, 29.4, 24.2, 22.9, 14.3.
<1-3> Synthesis of 2,2'-(1,4-
phenylenebis(methylene))bis(2-
octylpropane-1,3-diol) (11)
2,2'-(1,4-phenylenebis(methylene))bis(2-octylpropane-1,3-diol) (11) was
synthesized with a yield of 90% according to the general procedure for
reduction of
an ester using LAH of Example 1-3. 11-1 NMR (400MHz, CD30D): 6 7.10 (s, 414),
3.41-3.53 (m, 8H), 2.56 (s, 4H), 1.34-1.21 (m, 24H), 1.12-1.08 (m, 4H), 0.88
(t, J =
36

CA 02997394 2018-03-02
7.2 Hz, 6H); 13C NMR (100MHz, CD30D): 8 137.1, 131.3, 65.9, 44.1, 37.5, 33.3,
32.1, 31.9, 31.0, 30.9, 30.7, 24.1, 23.9, 14.7.
<1-4> Synthesis of P-XMA-C8a
P-XMA-C8a was synthesized with a yield of 80% according to the general
procedure for the glycosylation of Example 1-4. 11-1 NMR (400MHz, CDCI3):
8.10-8.05 (m, 8H), 8.02-7.96 (m,8H), 7.91-7.84 (m, 161-1), 7.82-7.79 (m, 16H),
7.74-
7.71 (m, 8H), 7.64-7.19 (m, 84H), 6.71 (s, 4H), 6.14-6.09 (m, 4H), 5.80-5.71
(m,
10H), 5.68-5.63 (m, 4H), 5.29-5.15 (m, 9H), 4.65-4.56 (m, 9H), 4.53-4.26 (m,
20H),
3.33 (d, J = 7.2 Hz, 2H), 3.23 (d, J = 8.8 Hz, 2H), 2.80 (d, J = 8.8 Hz, 2H),
2.69 (d, J
= 8.8 Hz, 211), 2.27 (d, J = 13.2 Hz, 2H), 1.97 (d, J = 13.2 Hz, 2H), 1.25-
1.11 (m,
28H), 0.92 (t, J = 6.8 Hz, 6H); 13C NMR (100MHz, CDCI3): 166.2, 166.1, 165.9,
165.9, 165.6, 165.2, 164.9, 164.9, 134.7, 133.9, 133.6, 133.3, 133.2, 130.1,
130.0,
129.8, 129.7, 129.6, 129.4, 129.3, 129.1, 128.9, 128.8, 128.5, 128.4, 100.8,
95.9, 74.8,
72.6, 72.3, 72.1, 71.4, 71.1, 70.5, 69.9, 69.1, 63.3, 62.6, 60.5, 41.6,35.9,
32.1,30.3,
30.0, 29.9, 29.8, 29.6, 22.8, 22.4, 21.2, 14.3.
<1-5> Synthesis of P-XMA-C8
P-XMA-C8 was synthesized with a yield of 95% according to the general
procedure for the deprotection of Example 1-5. The 11-1 NMR spectrum is shown
in
FIG. 6, and the 13C NMR spectrum is shown in FIG. 7. II-1 NMR (400MHz,
CD30D): 8 7.17 (s, 4H), 5.19-5.16 (m, 4H), 4.40-4.37 (m, 4H), 3.92-3.80 (m,
14H),
3.76-3.52 (m, 28H), 3.48-3.33 (m, 16H), 3.29-3.24 (m, 6H), 2.69 (d, J ¨ 13.2
Hz,
2H), 2.54 (d, J = 13.2 Hz, 2H), 1.34-1.20 (m, 28H), 0.90 (t, J = 6.8 Hz, 6H);
"C
NMR (100MHz, CD30D): 8. 131.5, 103.1, 78.1, 76.7, 75.2, 74.9, 74.3, 71.7,
62.9,
37

CA 02997394 2018-03-02
33.3, 30.9, 30.7, 23.9, 14.7; HRMS (El): calcd. for C781-1134044[M+Na]
1797.8146,
found 1797.8130.
<Preparation Example 2> Synthesis of P-XMA-C9
<2-1> Synthesis of diethyl 2-nonylmalonate (2)
Diethyl 2-nonylmalonate (2) was synthesized with a yield of 89% according
to the general procedure for the synthesis of Compound A of Example 1-1. IF1
NMR (400MHz, CDCI3): 6 4.22-4.16 (m, 411), 3.31 (t, J = 7.6 Hz, 1H), 1.90-1.86
(m,
21-1), 1.34-1.25 (m, 20H), 0.87 (t, J = 7.2 Hz, 3H); 13C NMR (100MHz, CDCI3):
6
169.8, 61.5, 52.3, 33.1, 29.8, 29.7, 29.5, 29.4, 28.9, 27.5, 22.9, 14.3.
<2-2> Synthesis of tetraethyl 2,2'-(1,4-phenylenebis(methylene))bis(2-
nonylmalonate) (7)
Tetraethyl 2,2'-(1,4-phenylenebis(methylene))bis(2-nonylmalonate) (7) was
synthesized with a yield of 81% according to the general procedure for the
introduction of a xylene linker of Example 1-2. 11-1 NMR (400MHz, CDC13): 6
6.95
(s, 4H), 4.20-4.11 (m, 811), 3.17 (s, 41-1), 1.75-1.73 (m, 411), 1.25-1.20 (m,
40H), 0.88
(t, J = 7.2 Hz, 6H); 13C NMR (100MHz, CDC13): 6 171.6, 135.1, 129.9, 61.3,
58.9,
37.8, 32.0, 31.9, 29.9, 29.5, 29.4, 24.2, 22.9, 14.3.
<2-3> Synthesis of 2,2'-(1,4-
phenylenebis(methylene))bis(2-
nonylpropane-1,3-diol) (12)
2,2' -(1,4-pheny leneb s(methy lene))bis(2-n ony Ipropane-1,3-diol) (12) was
synthesized with a yield of 90% according to the general procedure for the
reduction
of an ester using LAH of Example 1-3. NMR (400MHz,
CD30D): 6 7.10 (s,
4H), 3.41-3.53 (m, 8H), 2.56 (s, 4H), 1.34-1.21 (m, 28H), 1.12-1.08 (m, 4H),
0.88 (t,
38

CA 02997394 2018-03-02
J= 7.2 Hz, 6H); I3C NMR (100MHz, CD30D): 8 137.1, 131.3, 65.9, 44.1, 37.5,
33.3,
32.1, 31.9, 31.0, 30.9, 30.7, 24.1, 23.9, 14.7.
<2-4> Synthesis of P-XMA-C9a
P-XMA-C9a was synthesized with a yield of 82% according to the general
procedure for the glycosylation of Example 1-4. 11-1 NMR (400MHz, CDC13): 8
8.10-8.05 (m, 81-1), 8.02-7.96 (m,8H), 7.91-7.84 (m, 1611), 7.82-7.79 (m,
16H), 7.74-
7.71 (m, 811), 7.64-7.19 (m, 8411), 6.76 (s, 4H), 6.20-6.15 (m, 4H), 5.84-5.76
(m,
101-1), 5.72-5.68 (m, 411), 5.35-5.20 (m, 9H), 4.67-4.62 (m, 9H), 4.58-4.36
(m, 20H),
3.38 (d, J = 7.2 Hz, 2H) 3.26 (d, J = 8.8 Hz, 2H), 2.89 (d, J = 8.8 Hz, 2H),
2.72 (d, J
= 8.8 Hz, 2H), 2.30 (d, J = 13.2 Hz, 2H), 2.01 (d, J = 13.2 Hz, 2H), 1.32-1.24
(m,
32H), 0.92 (t, J = 6.8 Hz, 6H); 13C NMR (100MHz, CDC13): 8 166.2, 166.1,
165.9,
165.6, 165.2, 164.9, 134.7, 133.9, 133.6, 133.3, 133.2, 130.1, 129.8, 129.7,
129.6,
129.5, 129.3, 129.1, 128.9, 128.8, 128.5, 128.4, 100.8, 95.9, 74.8, 72.6,
72.3, 72.1,
71.4, 71.1, 70.5, 69.9, 69.1, 63.3, 62.6, 60.5, 41.6,35.9, 32.1,30.3, 30.0,
29.9, 29.8,
29.6, 22.9, 22.4, 21.2, 14.3.
<2-5> Synthesis of P-XMA-C9
P-XMA-C9 was synthesized with a yield of 94% according to the general
procedure for the deprotection of Example 1-5. FIG. 8 shows the 1H NMR
spectrum, and FIG. 9 shows the 13C NMR spectrum. 11-1 NMR (400MHz, CD30D):
8 7.18 (s, 4H), 5.19-5.16 (m, 4H), 4.40-4.37 (m, 4H), 3.92-3.80 (m, 14H), 3.76-
3.52
(m, 28H), 3.48-3.33 (m, 16H), 3.29-3.24 (m, 6H), 2.68 (d, J = 13.2 Hz, 2H),
2.54 (d,
J = 13.2 Hz, 2H), 1.37-1.16 (m, 32H), 0.92-0.88 (t, J = 6.8 Hz, 611); 13C NMR
(100MHz, CD30D): .5 136.8, 131.5, 105.1, 103.0, 81.6, 81.5, 78.1, 76.7, 75.2,
75.0,
39

CA 02997394 2018-03-02
74.9, 74.3, 71.7, 62.9, 62.5, 43.6, 33.3, 31.9, 31.8, 31.0, 30.9, 30.7, 23.9,
14.7;
HRMS (El): calcd. for Cs0H138044[M+Na] 1825.8459, found 1825.8451.
<Preparation Example 3> Synthesis of P-XMA-C10
<3-1> Synthesis of diethyl 2-decylmalonate (3)
Diethyl 2-decylmalonate (3) was synthesized with a yield of 89% according
to the general procedure for the synthesis of Compound A of Example 1-1. 1H
NMR (400MHz, CDC13): 54.22-4.17 (m, 4H), 3.31 (t,J = 7.6 Hz, 1H), 1.91-1.87
(m,
2H), 1.34-1.25 (m, 22H), 0.87 (t, J = 7.2 Hz, 3H); 13C NMR (100MHz, CDCI3):
169.8, 61.5, 52.3, 32.1, 29.8, 29.7, 29.5, 29.4, 28.9, 27.5, 22.9, 14.3.
<3-2> Synthesis of tetraethyl 2,2'-(1,4-phenylenebis(methylene))bis(2-
decylmalonate) (8)
Tetraethyl 2,2' -(1,4-pheny lenebis(methy lene))bis(2-decy lmalonate)) (8) was
synthesized with a yield of 82% according to the general procedure for the
introduction of a xylene linker of Example 1-2. 111 NMR (400MHz, CDC13): 8
6.95
(s, 4H), 4.17-4.13 (m, 8H), 3.17 (s, 411), 1.75-1.73 (m, 4H), 1.25-1.22 (m,
44H), 0.88
(t, J = 7.2 Hz, 6H); 13C NMR (100MHz, CDC13): 8 171.6, 135.1, 129.7, 61.3,
58.8,
37.7, 32.1, 31.9, 29.9, 29.7, 29.6, 29.6, 22.2, 14.3.
<3-3> Synthesis of 2,2'-(1,4-
phenylenebis(methylene))bis(2-
decylpropane-1,3-diol) (13)
2,2' -(1,4-phenylenebis(methylene))b is(2-decylpropane-1,3-diol) (13) was
synthesized with a yield of 89% according to the general procedure for
reduction of
an ester using LAH of Example 1-3. 114 NMR (400MHz, CD30D): 8 7.10 (s, 4H),
3.41-3.35 (m, 8H), 2.56 (s, 4H), 1.34-1.21 (m, 321-1), 1.12-1.08 (m, 4H), 0.88
(t, J =-

CA 02997394 2018-03-02
7.2 Hz, 6H); 13C NMR (100MHz, CD30D): 8 137.1, 131.3, 65.9, 44.1, 37.5, 33.3,
32.1, 31.9, 31.0, 30.9, 30.7, 24.1, 23.9, 14.7.
<3-4> Synthesis of P-XMA-C10a
P-XMA-ClOa was synthesized with a yield of 82% according to the general
procedure for the glycosylation of Example 1-4. 'H NMR (400MHz, CDC13): 8.10-
8.05 (m, 8H), 8.02-7.96 (m,8H), 7.91-7.84 (m, 16H), 7.82-7.79 (m, I6H), 7.74-
7.71
(m, 8H), 7.64-7.19 (m, 84H), 6.71 (s, 4H), 6.15-6.10 (m, 4H), 5.81-5.72 (m,
10H),
5.69-5.64 (m, 4H), 5.30-5.15 (m, 9H), 4.65-4.57 (m, 9H), 4.53-4.26 (m, 20H),
3.35
(d, J = 7.2 Hz, 2H), 3.22 (d, J = 8.8 Hz, 2H), 2.81 (d, J = 8.8 Hz, 2H), 2.69
(d, J =
8.8 Hz, 2H), 2.25 (d, J = 13.2 Hz, 2H), 2.04 (d,J= 13.2 Hz, 2H), 1.27-1.21 (m,
36H),
0.92 (t, J = 6.8 Hz, 6H); 13C NMR (100MHz, CDCI3): 8 166.2, 166.1, 165.9,
165.6,
165.2, 164.9, 134.7, 133.9, 133.6, 133.3, 133.2, 130.1, 130.0, 129.8, 129.7,
129.6,
129.5, 129.4, 129.3, 129.1, 128.9, 128.8, 128.5, 128.4, 100.8, 95.9, 95.8,
74.8, 72.6,
72.3, 72.1, 71.4, 71.1, 70.5, 69.9, 69.1, 63.3, 62.6, 60.5, 41.6, 35.9, 32.1,
30.3, 30.0,
29.9, 29.8, 29.6, 22.8, 22.4, 21.2, 14.3.
<3-5> Synthesis of P-XMA-C10
P-XMA-C10 was synthesized with a yield of 95% according to the general
procedure for the deprotection of Example 1-5. FIG. 10 shows the 111 NMR
spectrum, and FIG. 11 shows the 13C NMR spectrum. 1H NMR (400MHz,
CD30D): 8 7.17 (s, 4H), 5.19-5.16 (m, 411), 4.40-4.37 (in, 4H), 3.90-3.81 (in,
I4H),
3.73-3.55 (m, 28H), 3.49-3.24 (m, I6H), 3.29-3.24 (m, 6H), 2.68 (d, J = 13.2
Hz,
2H), 2.54 (d, J = 13.2 Hz, 2H), 1.37-1.16 (m, 28H), 0.90 (t, J = 6.8 Hz, 6H);
DC
NMR (100MHz, CD30D): 6 136.8, 131.5, 105.1, 105.0, 103.0, 81.6, 81.5, 78.1,
76.6,
41

CA 02997394 2018-03-02
75.2, 75.0, 74.9, 74.3, 71.6, 62.9, 62.4, 43.6, 33.3, 31.8, 31.1, 30.9, 30.9,
30.7, 23.9,
14.7; HRMS (El): calcd. for C821-1142044[M+Na] 1853.8772, found 1853.8759.
<Preparation Example 4> Synthesis of P-XMA-Cll
<4-1> Synthesis of diethyl 2-undecylmalonate (4)
Diethyl 2-undecylmalonate (4) was synthesized with a yield of 89%
according to the general procedure for the synthesis of Compound A of Example
1-1.
NMR (400MHz, CDC13): 8 4.23-4.16 (m, 4H), 3.31 (t, J = 7.6 Hz, 111), 1.90-1.87
(m, 211), 1.30-1.24 (m, 24H), 0.87 (t, J = 7.2 Hz, 3H); 13C NMR (100MHz,
CDC13):
8 169.8, 61.5, 52.3, 33.1, 29.8, 29.7, 29.6, 29.4, 28.9, 27.5, 22.9, 14.3.
<4-2> Synthesis of tetraethyl 2,2'-(1,4-phenylenebis(methylene))bis(2-
undecylmalonate) (9)
Tetraethyl 2,2' -(1,4-pheny lenebis(methylene))bis(2-undecy lmalonate) (9)
was synthesized with a yield of 82% according to the general procedure for the
introduction of a xylene linker of Example 1-2. NMR (400MHz,
CDCI3): 5 6.96
(s, 411), 4.21-4.0 (m, 811), 3.18 (s, 411), 1.76-1.74 (m, 4H), 1.27-1.20 (m,
48H), 0.88
(t, J = 7.2 Hz, 6H); 13C NMR (100MHz, CDCI3): 5 171.6, 135.0, 129.9, 61.3,
58.9,
37.8, 32.1, 31.9, 29.9, 29.8, 29.6, 29.5, 22.3, 22.9, 14.3.
<4-3> Synthesis of 2,2'41,4-
phenylenebis(methylene))bis(2-
undecylpropane-1,3-diol) (14)
2,2'-(1,4-phenylenebis(methylene))bis(2-undecylpropane-1,3-diol) (14) was
synthesized with a yield of 87% according to the general procedure for the
reduction
of an ester using LAH of Example 1-3. 11-1 NMR (400MHz, CD30D): 8 7.10 (s,
4H), 3.41-3.35 (m, 814), 2.56 (s, 4H), 1.34-1.21 (m, 36H), 1.21-1.08 (m, 4H),
0.88 (t,
42

CA 02997394 2018-03-02
J = 7.2 Hz, 6H); '3C NMR (100MHz, CD30D): 8 137.1, 131.3, 65.9, 44.1, 37.5,
33.3,
32.1, 31.9, 31.0, 30.9, 30.9, 24.1, 23.9, 14.7.
<4-4> Synthesis of P-XMA-Cll a
P-XMA-Clla was synthesized with a yield of 80% according to the general
procedure for the glycosylation of Example 1-4. 11-1 NMR (400MHz, CDC13):
8.10-8.05 (m, 8H), 8.02-7.96 (m,8H), 7.91-7.84 (m, 16H), 7.82-7.79 (m, 16H),
7.74-
7.71 (m, 8H), 7.64-7.19 (m, 84H), 6.71 (s, 4H), 6.15-6.10 (m, 4H), 5.81-5.72
(m,
10H), 5.69-5.64 (m, 4H), 5.30-5.15 (m, 9H), 4.65-4.57 (m, 9H), 4.53-4.26 (m,
201-1),
3.35 (d, J = 7.2 Hz, 2H), 3.22 (d, J = 8.8 Hz, 2H), 2.81 (d, J = 8.8 Hz, 2H),
2.70 (d, J
= 8.8 Hz, 2H), 2.26 (d, J = 13.2 Hz, 2H), 2.04 (d, J = 13.2 Hz, 2H), 1.27-1.21
(m,
40H), 0.93 (t, J = 6.8 Hz, 6H); 13C NMR (100MHz, CDC13): 6 166.2, 166.1,
165.9,
165.9, 165.6, 165.2, 164.9, 134.7, 133.9, 133.6, 133.3, 133.2, 130.1, 130.0,
129.8,
129.7, 129.6, 129.5, 129.4, 129.3, 129.1, 128.9, 128.8, 128.5, 128.4, 100.8,
100.7,
95.9, 95.8, 74.8, 72.6, 72.3, 72.1, 71.4, 71.1, 70.5, 69.9, 69.1, 63.3, 62.6,
60.5, 41.6,
35.9, 32.1, 30.3, 30.0, 29.9, 29.8, 29.6, 22.8, 22.4, 21.2, 14.3.
<4.5> Synthesis of P-XMA-C11
P-XMA-Cll was synthesized with a yield of 95% according to the general
procedure for the deprotection of Example 1-5. FIG. 12 shows the IFI NMR
spectrum, and FIG. 13 shows the 13C NMR spectrum. ill NMR (400MHz,
CD30D): 8 7.18 (s, 4H), 5.19-5.16 (m,4H), 4.40-4.37 (m, 4H), 3.93-3.80 (m, 141-
I),
3.76-3.53 (m, 28H), 3.49-3.24 (m, 161-1), 3.29-3.27 (m, 6H), 2.68 (d, J = 13.2
Hz,
2H), 2.54 (d, J = 13.2 Hz, 2H), 1.32-1.20 (m, 40H), 0.90 (t, J = 6.8 Hz, 6H);
13C
NMR (100MHz, CD30D): 8 136.8, 131.5, 105.1, 105.0, 103.1, 81.6, 78.1, 76.7,
75.2,
43

CA 02997394 2018-03-02
75.0, 74.9, 74.3, 71.7, 62.9, 62.5, 43.6, 33.3, 31.8, 31.1, 31.0, 30.9, 30.9,
30.7, 23.9,
14.7; HRMS (El): calcd. for C84H146044[M+Na] 1881.9085, found 1881.9091.
<Preparation Example 5> Synthesis of P-XMA-C12
<5-1> Synthesis of diethyl 2-dodecylmalonate (5)
Diethyl 2-dodecylmalonate (5) was synthesized with a yield of 89%
according to the general procedure for the synthesis of Compound A of Example
1-1.
II-1 NMR (400MHz, CDC13): 8 4.22-4.16(m, 4H), 3.31 (t,./ = 7.6 Hz, 11-1), 1.90-
1.87
(m, 2H), 1.30-1.25 (m, 26H), 0.87 (t, J = 7.2 Hz, 3H); 13C NMR (100MHz,
CDC13):
8 169.9, 61.5, 52.3, 32.1, 29.9, 29.9, 29.7, 29.6, 29.5, 29.4, 28.9, 27.5,
22.9, 14.4.
<5-2> Synthesis of tetraethyl 2,2'-(1,4-phenylenebis(methylene))bis(2-
dodecylmalonate) (10)
Tetraethyl 2,2' -( I ,4-pheny lenebis(methy lene))bis(2-dodecylmalonate) (10)
was synthesized with a yield of 82% according to the general procedure for the
introduction of a xylene linker of Example 1-2. 11-1NMR (400MHz, CDC13): 6
6.95
(s, 4H), 4.20-4.11 (m, 8H), 3.17 (s, 4H), 1.75-1.73 (m, 4H), 1.25-1.20 (m, 521-
1), 0.88
(t, J = 7.2 Hz, 6H); 13C NMR (100MHz, CDC13): 6 171.6, 135.1, 129.7, 61.3,
58.8,
37.7, 32.1, 31.9, 29.9, 29.7, 29.6, 29.6, 22.2, 14.3.
<5-3> Synthesis of 2,2'-(1,4-
phenylenebis(methylene))bis(2-
dodecylpropane-1,3-diol (15)
2,2' -(1,4-phenylenebis(methylene))bis(2-dodecylpropane-1,3-diol) (15) was
synthesized with a yield of 89% according to the general procedure for the
reduction
of an ester using LAH of Example 1-3. 11-1 NMR (400MHz, CD30D): 8 7.10 (s,
4H), 3.41-3.35 (m, 81-1), 2.56 (s, 4H), 1.34-1.21 (m, 40H), 1.21-1.08 (m, 4H),
0.88 (t,
44

CA 02997394 2018-03-02
J = 7.2 Hz, 6H); 13C NMR (100MHz, CD30D): 6 137.1, 131.3, 65.9, 44.2, 37.5,
33.3,
32.1, 31.9, 31.0, 30.9, 30.9, 24.1, 23.9, 14.7.
<5-4> Synthesis of P-XMA-C12a
P-XMA-C12a was synthesized with a yield of 81% according to the general
procedure for the glycosylation of Example 1-4. 1H NMR (400MHz, CDC13):
8.10-8.05 (m, 8H), 8.02-7.96 (m,811), 7.91-7.84 (m, 16H), 7.82-7.79 (m, 16H),
7.74-
7.71 (m, 8H), 7.64-7.19 (m, 8411), 6.71 (s, 4H), 6.15-6.10 (m, 414), 5.81-5.72
(m,
10H), 5.69-5.64 (m, 4H), 5.30-5.15 (m, 9H), 4.65-4.57 (m, 9H), 4.53-4.26 (m,
20H),
3.35 (d,J = 7.2 Hz, 2H), 3.22 (d, J 8.8 Hz, 2H), 2.81 (d,J ¨ 8.8 Hz, 2H), 2.69
(d, J
= 8.8 Hz, 2H), 2.25 (d, J = 13.2 Hz, 2H), 2.04 (d, J = 13.2 Hz, 2H), 1.27-1.21
(m,
4411), 0.92 (t, J = 6.8 Hz, 6H); 13C NMR (100MHz, CDC13): 6 166.2, 166.1,
165.9,
165.6, 165.2, 164.9, 134.7, 133.9, 133.6, 133.6, 133.3, 133.2, 130.1, 130.0,
129.8,
129.7, 129.6, 129.5, 129.4, 129.3, 129.1, 128.9, 128.8, 128.5, 128.4, 100.8,
95.9, 74.8,
72.6, 72.3, 72.1, 71.4, 71.1, 70.5, 69.9, 69.1, 63.3, 62.6, 60.5, 41.6, 35.9,
32.1, 30.3,
30.0, 29.9, 29.8, 29.6, 22.8, 22.4, 21.2, 14.3.
<5-5> Synthesis of P-XMA-C12
P-XMA-C12 was synthesized with a yield of 95% according to the general
procedure for the deprotection of Example 1-5. FIG. 14 shows the 1H NMR
spectrum, and FIG. 15 shows the 13C NMR spectrum. 114 NMR (400MHz,
CD30D): 6 7.18 (s, 4H), 4.19-51.16 (m, 4H), 4.40-4.38 (m, 4H), 3.94-3.80 (m,
14H),
3.76-3.55 (m, 28H), 3.53-3.24 (m, 16H), 3.30-3.26 (m, 6H), 2.68 (d, J = 13.2
Hz,
2H), 2.54 (d, J = 13.2 Hz, 214), 1.49-1.28 (m, 44H), 0.90 (t, J = 6.8 Hz, 6H);
13C
NMR (100MHz, CD30D); 6 136.8, 131.5, 105.1, 103.1, 81.6, 78.1, 76.7, 75.3,
75.0,

CA 02997394 2018-03-02
74.9, 74.3, 71.7, 62.9, 62,4, 43.6, 33.3, 31.8, 31.0, 30.9, 30.7, 23.9, 14.7;
HRMS (El):
calcd. for C86F1150044[M+Nar 1909.9398, found 1909.9387.
<Preparation Example 6> Synthesis of P-XGA-C4
Diethyl 2-butylmalonate was synthesized according to the general procedure
for the synthesis of Compound A of Example 1-1. Tetraethyl 2,2'41,4-
phenylenebis(methylene))bis(2-butylmalonate) was synthesized according to the
general procedure for the introduction of a xylene linker of Example 1-2.
2,2'41,4-
phenylenebis(methylene))bis(2-butylpropane-1,3-diol) was synthesized according
to
the general procedure for the reduction of an ester using LAH of Example 1-3.
P-
XGA-C4a was synthesized using perbenzoylated glueosylbromide instead of
perbenzoylated maltosylbromide in the general procedure for the glycosylation
of
Example 1-4. P-XGA-C4 was synthesized according to the general procedure for
the deprotection of Example 1-5.
<Preparation Example 7> Synthesis of P-XGA-05
Diethyl 2-pentylmalonate was synthesized according to the general
procedure for the synthesis of Compound A of Example 1-1. Tetraethyl 2,2'-(1,4-
phenylenebis(methylene))bis(2-pentylmalonate) was synthesized according to the
general procedure for the introduction of a xylene linker of Example 1-2. 2,2'-
(1,4-
phenylenebis(methylene))bis(2-pentylpropane-1,3-diol) was synthesized
according to
the general procedure for the reduction of an ester using LAH of Example 1-3.
P-
XGA-05a was synthesized using perbenzoylated glucosylbromide instead of
perbenzoylated maltosylbromide in the general procedure for a glycosylation of
Example 1-4. P-XGA-05 was synthesized according to the general procedure for
the deprotection of Example 1-5.
46

CA 02997394 2018-03-02
<Preparation Example 8> Synthesis of P-XGA-C6
Diethyl 2-hexylmalonate was synthesized according to the general procedure
for the synthesis of Compound A of Example 1-1. Tetraethyl 2,2'-
(1,4-
phenylenebis(methylene))bis(2-hexylmalonate) was synthesized according to the
.. general procedure for the introduction of a xylene linker of Example 1-2.
2,2'-(1,4-
phenylenebis(methylene))bis(2-hexylpropane-1,3-diol) was synthesized according
to
the general procedure for the reduction of an ester using LAH of Example 1-3.
P-
XGA-C6a was synthesized using perbenzoylated glucosylbromide instead of
perbenzoylated maltosylbromide in the general procedure for the glycosylation
of
.. Example 1-4. P-XGA-C6 was synthesized according to the general procedure
for
the deprotection of Example 1-5.
<Preparation Example 9> Synthesis of M-XMA-Cll
<9-1> Synthesis of diethyl 2-undecylmalonate (1)
Diethyl 2-undecylmalonate (1) was synthesized with a yield of 91%
.. according to the general procedure for the synthesis of Compound A of
Example 2-1.
111 NMR (400 MHz, CDC13): 5 4.23-4.16 (m, 4H), 3.31 (t, J = 7.6 Hz, 1H), 1.90-
1.87
(m, 2H), 1.30-1.24 (m, 24H), 0.87 (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz,
CDCI3):
8 169.8, 61.5, 52.3, 33.1, 29.8, 29.7, 29.6, 29.4, 28.9, 27.5, 22.9, 14.3.
<9-2> Synthesis of tetraethyl 2,2'-(1,3-phenylenebis(methylene))bis(2-
undecylmalonate) (6')
Tetraethyl 2,2'-(1,3-phenylenebis(methylene))bis(2-undecylmalonate) (6')
was synthesized with a yield of 82% by introducing an m-xylene linker
according to
the general procedure for the introduction of a xylene linker of Example 2-2.
1H
NMR (400 MHz, CDCI3): 5 7.12 (t, J = 7.6 Hz, 1H), 6.93-6.90 (m, 2H), 6.82 (s,
1H),
47

CA 02997394 2018-03-02
4.23-4.10 (m, 8H), 3.17 (s, 4H), 1.76-1.73 (m, 4H), 1.32-1.21 (m, 48H), 0.88
(t, J =
6.8 Hz, 6H); 13C NMR (100 MHz, CDC13): 5 171.6, 136.4, 131.9,128.6, 128.2,
61.3,
58.9, 38.2, 32.1, 31.9.29.9, 29.6, 24.4, 22.9,14.3.
<9-3> Synthesis of 2,2'-(1,3-
phenylenebis(methylene))bis(2-
undecylpropane-1,3-diol) (11')
2,2'-(1,3-phenylenebis(methylene))bis(2-undecylpropane-1,3-diol) ( I 1') was
synthesized with a yield of 87% according to the general procedure for the
reduction
of an ester using LAH of Example 2-3. 11-1NMR (400 MHz, CDC13): 8 7.28 (s, I
H),
7.19 (t, J = 6.8 Hz, 1H), 6.99 (d, J = 7.2 Hz, 2H), 3.57 (d, J = 7.2 Hz, 4H),
3.45 (d, J
.. = 7.2 Hz, 4H), 2.69 (s, 4H), 1.34-1.09 (m, 40H), 0.88 (t, J = 6.8 Hz, 6H);
13C NMR
(100 MHz, CDCI3): ö 137.9, 133.5, 128.2, 127.8, 68.4, 43.0, 36.8, 32.2, 31.5,
30.8,
29.9, 29.6, 23.2, 22.9, 14.4.
<9-4> Synthesis of M-XMA-C ha
M-XMA-Cl 1 a was synthesized with a yield of 73% according to the general
procedure for the glycosylation of Example 2-4. II-I NMR (400 MHz, CDCI3): 8
8.17 (d, J = 7.2 Hz, 4H), 8.09-7.96 (m, 24H), 7.89-7.82 (m, 20H), 7.75-7.72
(m, 8H),
7.57-7.19 (m, 84H), 6.87 (t, J = 7.2 Hz, 1H), 6.72-6.70 (m, 2H), 6.65 (s, 1H),
6.17-
6.09 (m, 4H), 5.76-5.57 (m, 10H), 5.33-5.24 (m, 4H), 5.20-5.09 (m, 4H), 4.74-
4.65
(m, 10H), 4.54-4.11 (m, 20H), 3.20 (d, J = 8.8 Hz, 2H), 3.11 (d, J = 8.8 Hz,
2H),
3.01 (d, J = 8.8 Hz, 21-1), 2.81 (d, J = 8.8 Hz, 2H), 2.47 (d, J = 8.8 Hz,
2H), 2.30 (d, J
= 8.8 Hz, 2H), 1.29-1.13 (m, 40H), 0.87 (t, J = 7.2 Hz, 6H); 13C NMR (100 MHz,
CDC13): 5 166.7, 166.0, 165.8, 165.5, 165.4, 165.2, 165.0, 164.9, 164.7,
135.9, 134.0,
133.6, 133.5, 133.3, 133.2, 132.9, 130.2, 130.1, 130.0, 129.9, 129.8, 129.7,
129.6,
129.5, 129.3, 129.2, 129.1, 128.9, 128.8, 128.7, 128.5, 128.4, 128.3, 127.8,
100.9,
48

CA 02997394 2018-03-02
100.6, 96.4, 95.4, 74.7, 72.3, 72.1, 71.9, 71.8, 71.4, 71.0, 70.1, 69.2, 68.9,
62.8, 62.5,
41.6, 32.1, 30.4, 30.0, 29.9, 29.8, 29.5, 22.8, 22.3, 14.3.
<9-5> Synthesis of M-XMA-Cll
M-XMA-Cll was synthesized with a yield of 95% according to the general
procedure for the deprotection of Example 2-5. FIG. 16 shows the 114 NMR
spectrum, and FIG. 17 shows the 13C NMR spectrum. 114 NMR (400 MHz,
CD30D): 5 7.18 (s, 1H), 7.12-7.10 (m, 3H), 5.21-5.17 (m, 4H), 4.42-4.37 (m,
4H),
3.92-3.82 (m, I4H), 3.75-3.51 (m, 281-1), 3.48-3.32 (m, 16H), 3.31-3.25 (m,
6H), 2.72
(d, = 13.2 Hz, 2H), 2.63 (d, J = 13.2 Hz, 2H), 1.34-1.23 (m, 40H), 0.90 (t,
J = 6.8
Hz, 61-1); 13C NMR (100 MHz, CD30D): 6 138.8, 129.7, 105.1, 105.0, 103.0,
81.6,
81.5, 78.1, 76.6, 75.2, 74.9, 74.3, 72.9, 72.7, 71.6, 62.9, 62.4, 49.8, 49.6,
49.4, 48.7,
48.5, 43.7, 37.9, 33.3, 32.2, 31.9, 31.1, 30.9, 30.7, 24.1, 23.9, 14.7; HRMS
(El):
calcd. for C84H146044 [M+Na] 1881.9085, found 1881.9080.
<Preparation Example 10> Synthesis of M-XMA-C12
<10-1> Synthesis of diethyl 2-dodecylmalonate (2)
Diethyl 2-dodecylmalonate (2) was synthesized with a yield of 89%
according to the general procedure for the synthesis of Compound A of Example
2-1.
NMR (400 MHz, CDC13): 5 4.22-4.16 (m, 4H), 3.31 (t,J = 7.6 Hz, 1H), 1.90-1.87
(m, 2H), 1.30-1.25 (m, 26H), 0.87 (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz,
CDC13):
5 169.9, 61.5, 52.3, 32.1, 29.9, 29.7, 29.6, 29.5, 29.4, 28.9, 27.5, 22.9,
14.4.
<10-2> Synthesis of tetraethyl 2,2'-(1,3-phenylenebis(methylene))bis(2-
dodecylmalonate) (7')
Tetraethyl 2,2'-(1,3-phenylenebis(methylene))bis(2-dodecylmalonate) (7')
was synthesized with a yield of 80% by introducing an m-xylene linker
according to
49

CA 02997394 2018-03-02
the general procedure for the introduction of a xylene linker of Example 2-2.
11-1
NMR (400 MHz, CDC13): 5 7.12 (t, J = 7.6 Hz, 1H), 6.92-6.90 (m, 2H), 6.81 (s,
1H),
4.21-4.12 (m, 8H), 3.16 (s, 4H), 1.75-1.57 (m, 4H), 1.30-1.21 (m, 52H), 0.88
(t, J =
6.8 Hz, 6H); I3C NMR (100 MHz, CDC13): 5171.6, 136.4, 131.9, 128.6, 128.2,
61.3,
58.9, 32.1, 29.8, 29.6, 29.5, 22.9, 14.4, 14.3.
<10-3> Synthesis of 2,2'-(1,3-
phenylenebis(methylene))bis(2-
dodecylpropane-1,3-diol) (12')
2,2' -(1,3-phenylenebis(methylene))bis(2-dodecylpropane-1,3-diol) (12') was
synthesized with a yield of 88% according to the general procedure for the
reduction
of an ester using LAH of Example 2-3. 114 NMR (400 MHz, CDCI3): 8 7.28 (s,
1H),
7.19 (t, J = 6.8 Hz, 1H), 6.99 (d, J = 7.2 Hz, 211), 3.57 (d, J = 7.2 Hz, 4H),
3.45 (d, J
= 7.2 Hz, 41-1), 2.70 (s, 41-1), 1.33-1.09 (m, 4411), 0.88 (t, J = 6.8 Hz,
611); 13C NMR
(100 MHz, CDC13): S 137.9, 133.5, 128.2, 127.8, 68.4, 43.0, 36.8, 32.2, 31.5,
30.8,
29.9, 29.6, 23.2, 22.9, 14.4.
<10-4> Synthesis of M-XMA-C12a
M-XMA-C12a was synthesized with a yield of 70% according to the general
procedure for the glycosylation of Example 2-4. 11-1 NMR (400 MHz, CDC13): 8
8.17 (d, J = 7.2 Hz, 4H), 8.09-7.96 (m, 24H), 7.89-7.82 (m, 20H), 7.75-7.72
(m, 8H),
7.57-7.19 (m, 84H), 6.88 (t, J = 7.2 Hz, 1H), 6.73-6.71 (m, 2H), 6.65 (s, 1H),
6.17-
6.10 (m, 4H), 5.76-5.57 (m, 10H), 5.33-5.24 (m, 4H), 5.20-5.09 (m, 4H), 4.74-
4.65
(m, 10H), 4.54-4.11 (m, 2011), 3.21 (d, J = 8.8 Hz, 2H), 3.11 (d, J = 8.8 Hz,
2H),
3.01 (d, J = 8.8 Hz, 2H), 2.81 (d, J = 8.8 Hz, 2H), 2.47 (d, J = 8.8 Hz, 2H),
2.30 (d, J
= 8.8 Hz, 2H), 1.29-1.13 (m, 40H), 0.87 (t, J = 7.2 Hz, 6H); 13C NMR (100 MHz,
CDC13): 5 166.7, 166.0, 165.8, 165.5, 165.4, 165.2, 165.0, 164.9, 164.7,
135.9, 134.0,

CA 02997394 2018-03-02
133.6, 133.5, 133.3, 133.2, 132.9, 130.2, 130.1, 130.0, 129.9, 129.8, 129.7,
129.6,
129.5, 129.3, 129.2, 129.1, 128.9, 128.8, 128.7, 128.5, 128.4, 128.3, 127.8,
100.9,
100.6, 96.4, 95.4, 74.7, 72.3, 72.1, 71.9, 71.8, 71.4, 71.0, 70.1, 69.2, 68.9,
62.8, 62.5,
41.6, 32.1, 30.4, 30.0, 29.9, 29.8, 29.5, 22.8, 22.3, 14.3.
<10-5> Synthesis of M-XMA-C12
M-XMA-C12 was synthesized with a yield of 93% according to the general
procedure for the deprotection of Example 2-5. FIG. 18 shows the IFI NMR
spectrum, and FIG. 19 shows the 13C NMR spectrum. 11-1 NMR (400 MHz,
CD30D): 6 7.19 (s, 1H), 7.12-7.10 (m, 3H), 5.21-5.17 (m, 4H), 4.42-4.37 (m,
4H),
3.92-3.82 (m, 14H), 3.75-3.51 (m, 28H), 3.48-3.32 (m, 16H), 3.31-3.25 (m, 6H),
2.71
(d, J = 13.2 Hz, 2H), 2.62 (d, J = 13.2 Hz, 2H), 1.37-1.23 (m, 44H), 0.90 (t,
J = 6.8
Hz, 6H); 13C NMR (100 MHz, CD30D): 6 138.8, 129.8, 105.1, 105.0, 103.1, 81.6,
81.5, 78.1, 76.7, 75.2, 74.9, 74.3, 71.6, 62.9, 62.4, 43.7, 33.3, 31.9, 31.1,
31.0, 30.7,
23.9, 14.7; HRMS (El): calcd. for C86H150044 [M+Nar 1909.9398, found
1909.9402.
<Preparation Example 11> Synthesis of M-XMA-C14
<11-1> Synthesis of diethyl 2-tetradecylmalonate (3)
Diethyl 2-tetradecylmalonate (3) was synthesized with a yield of 90%
according to the general procedure for the synthesis of Compound A of Example
2-1.
11-1 NMR (400 MHz, CDC13): 6 4.22-4.16(m, 4H), 3.31 (t, J = 7.6 Hz, 1H), 1.90-
1.87
(m, 2H), 1.30-1.25 (m, 30H), 0.87 (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz,
CDC13):
6 169.9, 61.5, 52.3, 32.1, 29.9, 29.7, 29.6, 29.5, 29.4, 28.9, 27.5, 22.9,
14.4.
<11-2> Synthesis of tetraethyl 2,2'-(1,3-phenylenebis(methylene))bis(2-
tetradecylmalonate) (8')
51

CA 02997394 2018-03-02
Tetraethyl 2,2'-(1,3-phenylenebis(methy lene))bis(2-tetradecylmalonate) (8')
was synthesized with a yield of 83% by introducing an m-xylene linker
according to
the general procedure for the introduction of a xylene linker of Example 2-2.
11-1
NMR (400 MHz, CDC13): ö 7.12 (t, J = 7.6 Hz, 1H), 6.92-6.90 (m, 2H), 6.81 (s,
1H),
4.21-4.12 (m, 8H), 3.16 (s, 4H), 1.75-1.57 (m, 4H), 1.30-1.21 (m, 60H), 0.88
(t, J =
6.8 Hz, 6H); I3C NMR (100 MHz, CDC13): 45 171.6, 136.4, 131.9, 128.6, 128.2,
61.3,
58.9, 32.1, 29.8, 29.6, 29.5, 22.9, 14.4, 14.3.
<11-3> Synthesis of 2,2'-(1,3-phenylenebis(methylene))bis(2-
tetradecylpropane-1,3-diol) (13')
2,2' -(1,3-pheny lenebis(methylene))bis(2-tetradecylpropane-1,3-diol) (13')
was synthesized with a yield of 85% according to the general procedure for the
reduction of an ester using LAH of Example 2-3. 11-1 NMR (400 MHz, CDC13):
7.28 (s, 1H), 7.19 (t, J = 6.8 Hz, I H), 6.99 (d, J ¨ 7.2 Hz, 2H), 3.57 (d, J
¨ 7.2 Hz,
4H), 3.45 (d, J = 7.2 Hz, 41-1), 2.70 (s, 4H), 1.33-1.09 (m, 52H), 0.88 (t, .1
= 6.8 Hz,
6H); 13C NMR (100 MHz, CDC13): 137.9, 133.5, 128.2, 127.8, 68.4, 43.0,
36.8,
32.2, 31.5, 30.8, 29.9, 29.6, 23.2, 22.9, 14.4.
<11-4> Synthesis of M-XMA-C14a
M-XMA-C14a was synthesized with a yield of 68% according to the general
procedure for the glycosylation of Example 2-4. 11-1. NMR (400 MHz, CDCI3):
8.17 (d, J = 7.2 Hz, 411), 8.09-7.96 (m, 2411), 7.89-7.82 (m, 20H), 7.75-7.72
(m, 8H),
7.57-7.19 (m, 84H), 6.87 (t, J = 7.2 Hz, 1H), 6.72-6.70 (m, 2H), 6.65 (s, 1H),
6.17-
6.09 (m, 4H), 5.76-5.57 (m, 10H), 5.33-5.24 (m, 4H), 5.20-5.09 (m, 4H), 4.74-
4.65
(m,10H), 4.54-4.11 (m, 20H), 3.20 (d, J = 8.8 Hz, 2H), 3.11 (d, J -= 8.8 Hz,
2H), 3.01
(d, J = 8.8 Hz, 2H), 2.81 (d, J = 8.8 Hz, 2H), 2.47 (d, J = 8.8 Hz, 2H), 2.30
(d, J =
52

CA 02997394 2018-03-02
8.8 Hz, 2H), 1.29-1.13 (m, 40H), 0.87 (t, J = 7.2 Hz, 6H); 13C NMR (100 MHz,
CDCI3): 8 166.7, 166.0, 165.8, 165.5, 165.4, 165.2, 165.0, 164.9, 164.7,
135.9, 134.0,
133.6, 133.5, 133.3, 133.2, 132.9, 130.2, 130.1, 130.0, 129.9, 129.8, 129.7,
129.6,
129.5, 129.3, 129.2, 129.1, 128.9, 128.8, 128.7, 128.5, 128.4, 128.3, 127.8,
100.9,
100.6, 96.4, 95.4, 74.7, 72.3, 72.1, 71.9, 71.8, 71.4, 71.0, 70.1, 69.2, 68.9,
62.8, 62.5,
41.6, 32.1, 30.4, 30.0, 29.9, 29.8, 29.5, 22.8, 22.3, 14.3.
<11-5> Synthesis of M-XMA-C14
M-XMA-C14 was synthesized with a yield of 96% according to the general
procedure for the deprotection of Example 2-5. FIG. 20 shows the IFI NMR
spectrum, and FIG. 21 shows the 13C NMR spectrum. 11-1 NMR (400 MHz,
CD30D): 8 7.18 (s, 1H), 7.12-7.10 (m, 3H), 5.20-5.16 (m, 4H), 4.42-4.37 (m,
4H),
3.92-3.82 (m, 14H), 3.75-3.51 (m, 28H), 3.48-3.32 (m, 16H), 3.31-3.25 (m, 6H),
2.71
(d, J = 13.2 Hz, 2H), 2.61 (d, J = 13.2 Hz, 2H), 1.39-1.23 (m, 52H), 0.90 (t,
J = 6.8
Hz, 6H); 13C NMR (100 MHz, CD30D): 8 138.8, 129.8, 105.1, 103.1, 99.2, 81.6,
.. 81.5, 78.1, 76.7, 75.2, 74.9, 74.3, 71.6, 62.9, 62.4, 43.7, 33.3, 31.9,
31.1, 30.9, 30.7,
23.9, 14.7; HRMS (El): calcd. for C9014158044 [M+Naf 1967.0058, found
1967.0087.
<Preparation Example 12> Synthesis of M-XMA-C16
<12-1> Synthesis of diethyl 2-hexadecylmalonate (4)
Diethyl 2-hexadecylmalonate (4) was synthesized with a yield of 86%
.. according to the general procedure for the synthesis of Compound A of
Example 2-1.
11-1 NMR (400 MHz, CDCI3): 6 4.23-4.16 (m, 41-1), 3.31 (t, J = 7.6 Hz, 111),
1.90-1.87
(m, 2H), 1.30-1.25 (m, 34H), 0.87 (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz,
CDC13):
8 169.9, 61.5, 52.3, 32.1, 29.9, 29.7, 29.6, 29.5, 29.4, 28.9, 27.5, 27.2,
22.9, 14.4.
53

CA 02997394 2018-03-02
<12-2> Synthesis of tetraethyl 2,2'-(1,3-phenylenebis(methylene))bis(2-
hexadecylmalonate) (9')
Tetraethyl 2,2' -(1,3-phenylenebis(methylene))bis(2-hexadecy lma lonate) (9')
was synthesized with a yield of 80% by introducing an m-xylene linker
according to
the general procedure for the introduction of a xylene linker of Example 2-2.
11-1
NMR (400 MHz, CDC13): 5 7.12 (t, J = 7.6 Hz, 1H), 6.92-6.90 (m, 2H), 6.81 (s,
1H),
4.21-4.12 (m, 8H), 3.16 (s, 4H), 1.75-1.57 (m, 4H), 1.30-1.21 (m, 68H), 0.88
(t, J =-
6.8 Hz, 6H); NMR (100 MHz,
CDC13): 5 171.6, 136.4, 131.9, 128.6, 128.2, 61.3,
58.9, 32.1, 29.8, 29.6, 29.5, 22.9, 14.4, 14.3.
<12-3> Synthesis of 2,2'-(1,3-phenylenebis(methylene))bis(2-
hexadecylpropane-1,3-diol) (14')
2,2' -(1,3-pheny lenebis(methy lene))bis(2-hexadecylpropane-1,3-diol) (14')
was synthesized with a yield of 80% according to the general procedure for the
reduction of an ester using LAH of Example 2-3. ill NMR (400 MHz, CDC13): 5
7.29 (s, 1H), 7.20 (t, J = 6.8 Hz, 1H), 6.99 (d, J = 7.2 Hz, 2H), 3.57 (d, J =
7.2 Hz,
4H), 3.45 (d, J = 7.2 Hz, 4H), 2.70 (s, 4H), 1.34-1.09 (m, 60H), 0.88 (t, J ¨
6.8 Hz,
6H); "C NMR (100 MHz, CDC13): 8 137.9, 133.5, 128.2, 127.8, 68.4, 43.0, 36.8,
32.2, 31.5, 30.8, 30.0, 29.9, 29.6, 23.2, 22.9, 14.4.
<12-4> Synthesis of M-XMA-C16a
M-XMA-C16a was synthesized with a yield of 68% according to the general
procedure for the glycosylation of Example 2-4. 111 NMR (400 MHz, CDCI3): 5
8.17 (d, J = 7.2 Hz, 4H), 8.09-7.96 (m, 24H), 7.89-7.82 (m, 20H), 7.75-7.72
(m, 8H),
7.57-7.19 (m, 84H), 6.87 (t, ./ = 7.2 Hz, 1H), 6.72-6.70 (m, 2H), 6.65 (s,
1H), 6.17-
6.09 (m, 4H), 5.76-5.57 (m, 10H), 5.33-5.24 (111, 4H), 5.20-5.09 (m, 4H), 4.74-
4.65
54

CA 02997394 2018-03-02
(m, 10H), 4.54-4.11 (m, 20H), 3.20 (d, J = 8.8 Hz, 21-1), 3.11 (d, J = 8.8 Hz,
2H),
3.01 (d, J = 8.8 Hz, 2H), 2.81 (d, J = 8.8 Hz, 2H), 2.47 (d, J 8.8 Hz, 2H),
2.30 (d, J
= 8.8 Hz, 2H), 1.29-1.13 (m, 4011), 0.87 (t, J = 7.2 Hz, 6H); 13C NMR (100
MHz,
CDC13): S 166.7, 166.0, 165.8, 165.5, 165.4, 165.2, 165.0, 164.9, 164.7,
135.9, 134.0,
133.6, 133.5, 133.3, 133.2, 132.9, 130.2, 130.1, 130.0, 129.9, 129.8, 129.7,
129.6,
129.5, 129.3, 129.2, 129.1, 128.9, 128.8, 128.7, 128.5, 128.4, 128.3, 127.8,
100.9,
100.6, 96.4, 95.4, 74.7, 72.3, 72.1, 71.9, 71.8, 71.4, 71.0, 70.1, 69.2, 68.9,
62.8, 62.5,
41.6, 32.1, 30.4, 30.0, 29.9, 29.8, 29.5, 22.8, 22.3, 14.3.
<12-5> Synthesis of M-XMA-C16
M-XMA-C16 was synthesized with a yield of 92% according to the general
procedure for the deprotection of Example 2-5. FIG. 22 shows the '14 NMR
spectrum, and FIG. 23 shows the "C NMR spectrum. '14 NMR (400 MHz,
CD30D): 8 7.18 (s, 1H), 7.15-7.09 (m, 3H), 5.20-5.16 (m, 4H), 4.41-4.37 (m,
4H),
3.92-3.82 (m, 14H), 3.75-3.51 (m, 28H), 3.48-3.32 (m, 16H), 3.31-3.25 (in, 6I-
1), 2.72
(d, J = 13.2 Hz, 2H), 2.59 (d, J = 13.2 Hz, 2H), 1.39-1.23 (m, 60H), 0.90 (t,
J = 6.8
Hz, 6H); "C NMR (100 MHz, CD30D): 8 138.8, 129.8, 105.0, 103.1, 81.6, 78.1,
76.7, 75.2, 74.9, 74.4, 71.6, 62.9, 62.4, 43.7, 33.3, 31.9, 31.1, 31.0, 30.9,
30.7, 23.9,
14.7; HRMS (El): calcd. for C9411166044 [M+Na] 2023.0684, found 2022.0645.
<Preparation Example 13> Synthesis of M-XMA-C18
<13-1> Synthesis of diethyl 2-octadecylmalonate (5)
Diethyl 2-octadecylmalonate (5) was synthesized with a yield of 88%
according to the general procedure for the synthesis of Compound A of Example
2-1.
II-1 NMR (400 MHz, CDCI3): 8 4.23-4.16 (m, 4H), 3.31 (t, J = 7.6 Hz, 1H), 1.90-
1.87
(m, 2H), 1.30-1.25 (m, 38H), 0.87 (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz,
CDC13):

CA 02997394 2018-03-02
6 169.9, 61.5, 52.3, 32.1, 29.9, 29.8, 29.7, 29.6, 29.5, 29.4, 28.9, 27.5,
27.2, 22.9,
14.4.
<13-2> Synthesis of tetraethyl 2,2'-(1,3-phenylenebis(methylene))bis(2-
octadecylmalonate) (10')
Tetraethyl 2,2' -(1,3-pheny lenebi s(methylene))bis(2-octadecy lmalonate)
(10') was synthesized with a yield of 81% by introducing an m-xylene linker
according to the general procedure for the introduction of a xylene linker of
Example
2-2. 11-1 NMR (400 MHz, CDC13): 8 7.12 (t, J = 7.6 Hz, IH), 6.92-6.90 (m, 2H),
6.81 (s, IH), 4.21-4.12 (m, 8H), 3.16 (s, 4H), 1.75-1.57 (m, 4H), 1.30-1.21
(m, 7614),
0.88 (t, J = 6.8 Hz, 6H); 13C NMR (100 MHz, CDCI3): 6 171.6, 136.4, 131.9,
128.6,
128.2, 61.3, 58.9, 32.1, 29.8, 29.6, 29.5, 23.2, 22.9, 14.4, 14.3.
<13-3> Synthesis of 2,2'-(1,3-phenylenebis(methylene))bis(2-
octadecylpropane-1,3-diol) (15')
2,2' -(1,3-pheny lenebis(methylene))bis(2-octadecy Ipropane- 1 ,3-diol)) (15')
was synthesized with a yield of 75% according to the general procedure for the
reduction of an ester using LAH of Example 1-3. 11-1 NMR (400 MHz, CDC13): 6
7.29 (s, 1H), 7.20 (t, J = 6.8 Hz, 1H), 6.99 (d, J = 7.2 Hz, 2H), 3.57 (d, J =
7.2 Hz,
4H), 3.45 (d, J = 7.2 Hz, 4H), 2.70 (s, 4H), 1.34-1.09 (m, 68H), 0.88 (t, J =
6.8 Hz,
6H); 13C NMR (100 MHz, CDCI3): 8 137.9, 133.5, 128.2, 127.8, 68.4, 43.0, 36.8,
32.2, 31.5, 30.8, 30.0, 29.9, 29.6, 23.2, 22.9, 14.4, 14.2.
<13-4> Synthesis of M-XMA-C18a
M-XMA-C18a was synthesized with a yield of 62% according to the general
procedure for the glycosylation of Example 2-4. 1H NMR (400 MHz, CDC13): 6
8.17 (d, J = 7.2 Hz, 411), 8.09-7.96 (m, 24H), 7.89-7.82 (m, 20H), 7.75-7.72
(m, 8H),
56

CA 02997394 2018-03-02
7.57-7.19 (m, 84H), 6.87 (t, J = 7.2 Hz, 1H), 6.72-6.70 (m, 2H), 6.65 (s, 1H),
6.17-
6.09 (m, 4H), 5.76-5.57 (m, 10H), 5.33-5.24 (m, 4H), 5.20-5.09 (m, 4H), 4.74-
4.65
(m, 10H), 4.54-4.11 (m, 20H), 3.20 (d, J = 8.8 Hz, 2H), 3.11 (d, J = 8.8 Hz,
2H),
3.01 (d, J = 8.8 Hz, 2H), 2.81 (d, J = 8.8 Hz, 2H), 2.47 (d, J = 8.8 Hz, 2H),
2.30 (d, J
= 8.8 Hz, 2H), 1.29-1.13 (m, 40H), 0.87 (t, J = 7.2 Hz, 6H); 13C NMR (100 MHz,
CDC13): 5 166.7, 166.0, 165.8, 165.5, 165.4, 165.2, 165.0, 164.9, 164.7,
135.9, 134.0,
133.6, 133.5, 133.3, 133.2, 132.9, 130.2, 130.1, 130.0, 129.9, 129.8, 129.7,
129.6,
129.5, 129.3, 129.2, 129.1, 128.9, 128.8, 128.7, 128.5, 128.4, 128.3, 127.8,
100.9,
100.6, 96.4, 95.4, 74.7, 72.3, 72.1, 71.9, 71.8, 71.4, 71.0, 70.1, 69.2, 68.9,
62.8, 62.5,
.. 41.6, 32.1, 30.4, 30.0, 29.9, 29.8, 29.5, 22.8, 22.3, 14.3.
<13-5> Synthesis of M-XMA-C18
M-XMA-C18 was synthesized with a yield of 90% according to the general
procedure for the deprotection of Example 2-5. FIG. 24 shows the 11-1 NMR
spectrum, and FIG. 25 shows the 13C NMR spectrum. 'H NMR (400 MHz, CD3OD
.. + 1 % (CD3)2S0): 6 7.18 (s, 1H), 7.15-7.09 (m, 3H), 5.20-5.16 (m, 4H), 4.41-
4.37 (m,
4H), 3.92-3.82 (m, 14H), 3.75-3.51 (m, 28H), 3.48-3.32 (m, 16H), 3.31-3.25 (m,
6H),
2.72 (d, J ¨ 13.2 Hz, 2H), 2.59 (d, J = 13.2 Hz, 2H), 1.39-1.23 (m, 68H), 0.90
(t, J =
6.8 Hz, 6H); 13C NMR (100 MHz, CD3OD + 1 % (CD3)2S0): 6 138.8, 129.8, 105.0,
103.1, 81.6, 78.1, 76.7, 75.2, 74.9, 74.4, 71.6, 62.9, 62.4, 43.7, 33.3, 31.9,
31.1, 30.8,
31.0, 30.9, 30.7, 23.9, 14.7; HR1VIS (El): calcd. for C9814174044 [M+Nal
2079.1310,
found 2079.1018.
<Preparation Example 14> Synthesis of 0-XMA-C11
<14-1> Synthesis of diethyl 2-undecylmalonate (1)
57

CA 02997394 2018-03-02
Diethyl 2-undecylmalonate (1) was synthesized with a yield of 91%
according to the general procedure for the synthesis of Compound A of Example
2-1.
'H NMR (400 MHz, CDC13): 8 4.23-4.16 (m, 4H), 3.31 (t, J = 7.6 Hz, 11-1), 1.90-
1.87
(m, 2H), 1.30-1.24 (m, 24H), 0.87 (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz,
CDC13):
8 169.8, 61.5, 52.3, 33.1, 29.8, 29.7, 29.6, 29.4, 28.9, 27.5, 22.9, 14.3.
<14-2> Synthesis of tetraethyl 2,2'-(1,2-phenylenebis(methylene))bis(2-
undecylmalonate) (6")
Tetraethyl 2,2' -(1,2-phenylenebis(methylene))bis(2-undecy lmalonate) (6")
was synthesized with a yield of 80% by introducing an o-xylene linker
according to
the general procedure for the introduction of a xylene linker of Example 2-2.
NMR (400 MHz, CDC13): 6 7.10-7.07 (m, 2H), 7.05-7.03 (m, 2H), 4.19-4.08 (m,
8H),
3.27 (s, 4H), 1.76-1.74 (m, 4H), 1.27-1.20 (m, 48H), 0.88 (t, J = 7.2Hz, 6H);
13C
NMR (100 MHz, CDC13): 8 171.7, 135.9, 126.8, 61.3, 59.2, 33.9, 32.1, 30.0,
29.9,
29.8, 29.6, 24.6, 22.9, 14.2.
<14-3> Synthesis of 2,2'-(1,2-phenylenebis(methylene))bis(2-
undecylpropane-1,3-diol) (11")
2,2' -(1,2-pheny lenebis(methy lene))bis(2-undecylpropane-1,3-diol) ( I 1"
)
was synthesized with a yield of 86% according to the general procedure for the
reduction of an ester using LAH of Example 2-3. 11-1 NMR (400 MHz, CDC13): 8
7.22-7.21 (m, 2H), 7.15-7.12 (m, 2H), 3.59-3.52 (m, 81-1), 184 (s, 4H), 1.43-
1.24 (m,
40H), 0.88 (t, J = 7.2Hz, 6H); I3C NMR (100 MHz, CDC13): 8 138.5, 124.7,
124.6,
66.9, 39.1, 35.9, 31.9, 31.2, 30.2, 29.6, 29.3, 22.7, 14.1.
<14-4> Synthesis of 0-XMA-Clla
58

CA 02997394 2018-03-02
0-XMA-C1 la was synthesized with a yield of 68% according to the general
procedure for the glycosylation of Example 2-4. 11-1 NMR (400 MHz, CDC13): 6
8.02-7.96 (m, 27H), 7.93-7.91 (m, 4H), 7.89-7.86 (m, 8H), 7.83-7.77 (m, 8H),
7.76-
7.74 (m, 8H), 7.67 (t, J = 7.2 Hz, 2H), 7.59 (t, J = 7.2 Hz, 2H), 7.54-7.24
(m, 81H),
7.13-7.11 (m, 2H), 6.54-6.52 (m, 2H), 6.18-6.11 (m, 4H), 5.75-5.63 (m, 8H),
5.37-
5.30 (m, 4H), 5.26-5.20 (m, 4H), 5.17-5.13 (m, 4H), 4.66-4.15 (m, 32H), 3.39
(d, J =
8.8 Hz, 2H), 3.21 (d, J = 8.8 Hz, 2H), 2.87 (d, J = 8.8 Hz, 2H), 2.75 (d, J =
8.8 Hz,
2H), 2.24 (d, J = 8.8 Hz, 2H), 2.22 (d, J = 8.8 Hz, 2H), 1.27-1.07 (m, 40H),
0.88 (t, J
= 7.2 Hz, 6H); 13C NMR (100 MHz, CDC13): 5 166.2, 166.1, 166.0, 165.9, 165.7,
165.6, 165.3, 165.2, 164.9, 136.3, 133.9, 133.7, 133.6, 133.4, 133.3, 130.1,
129.9,
129.8, 129.6, 129.4, 129.2, 129.1, 129.0, 128.9, 128.8, 128.7, 128.6, 128.5,
128.4,
100.9, 96.1, 95.6, 74.8, 72.2, 72.0, 71.9, 71.6, 71.4, 69.9, 96.2, 69.1, 62.8,
62.7, 42.4,
32.1, 31.6, 30.8, 30.1, 30.0, 29.9, 29.7, 29.6, 23.7, 22.9, 14.3.
<14-5> Synthesis of 0-XMA-C11
0-XMA-C11 was synthesized with a yield of 96% according to the general
procedure for the deprotection of Example 2-5. FIG. 26 shows the NMR
spectrum, and FIG. 27 shows the 13C NMR spectrum. 1H NMR (400 MHz,
CD30D): 6 7.26-7.24 (m, 2H), 7.09-7.07 (m, 2H), 5.19-5.16 (m, 4H), 4.40-4.37
(m,
4H), 3.92-3.80 (m, 14H), 3.73-3.52 (m, 281-1), 3.47-3.36 (m, 16H), 3.33-3.24
(m, 6H),
2.99 (d, J = 13.2 Hz, 2H), 2.75 (d, J = 13.2 Hz, 21-1), 1.33-1.21 (m, 40H),
0.90 (t, J =
7.2Hz, 6H); I3C NMR (100 MHz, CD30D): 6 139.3, 132.9, 105.0, 104.9, 103.1,
81.7,
78.1, 76.6, 75.2, 75.0, 74.9, 74.3, 73.3, 72.9, 71.6, 67.1, 62.9, 62.6, 62.5,
44.4, 33.3,
32.9, 31.9, 31.0, 30.9, 30.7, 24.4, 23.9, 15.6, 14.7; HRMS (El): calcd. for
C84H146044
[M+Nar 1881.9085, found 1881.9089.
59

CA 02997394 2018-03-02
<Preparation Example 15> Synthesis of 0-XMA-C12
<15-1> Synthesis of diethyl 2-dodecylmalonate (2)
Diethyl 2-dodecylmalonate (2) was synthesized with a yield of 89%
according to the general procedure for the synthesis of Compound A of Example
2-1.
Ili NMR (400 MHz, CDC13): 6 4.22-4.16 (m, 4H), 3.31 (t, J = 7.6 Hz, 1H), 1.90-
1.87
(m, 2H), 1.30-1.25 (m, 26H), 0.87 (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz,
CDC13):
8 169.9, 61.5, 52.3, 32.1, 29.9, 29.7, 29.6, 29.5, 29.4, 28.9, 27.5, 22.9,
14.4.
<15-2> Synthesis of tetraethyl 2,2'-(1,2-phenylenebis(methylene))bis(2-
dodecylmalonate) (7")
Tetraethyl 2,2' -(1,2-pheny lenebis(methy lene))bis(2-dodecylmalonate) (7")
was synthesized with a yield of 78% by introducing an o-xylene linker
according to
the general procedure for the introduction of a xylene linker of Example 2-2.
11-1
NMR (400 MHz, CDC13): 67.10-7.07 (in, 2H), 7.05-7.03 (in, 2H), 4.19-4.09 (m,
8H),
3.26 (s, 4H), 1.76-1.74 (m, 4H), 1.27-1.20 (m, 52H), 0.88 (t, J = 7.2Hz, 6H);
13C
NMR (100 MHz, CDC13): 6 171.7, 135.9, 126.8, 61.3, 59.2, 33.9, 32.1, 30.0,
29.9,
29.8, 29.6, 24.6, 22.9, 14.4, 14.2.
<15-3> Synthesis of 2,2'-(1,2-
phenylenebis(methylene))bis(2-
dodecylpropane-1,3-diol) (12")
2,2 '-(1,2-pheny lenebi s(methy lene))b is(2-dodecy 1propane-1,3-diol)
(12")
was synthesized with a yield of 83% according to the general procedure for the
reduction of an ester using LAH of Example 2-3. 11-1 NMR (400 MHz, CDC13):
7.10-7.07 (m, 2H), 7.05-7.03 (m, 2H), 4.19-4.09 (m, 8H), 3.26 (s, 4H), 1.76-
1.74 (m,
4H), 1.27-1.20 (m, 52H), 0.88 (t, J = 7.2Hz, 6H); 13C NMR (100 MHz, CDCI3): 6

CA 02997394 2018-03-02
171.7, 135.9, 126.8, 61.3, 59.2, 33.9, 32.1, 30.0, 29.9, 29.8, 29.6, 24.6,
22.9, 14.4,
14.2.
<15-4> Synthesis of 0-XMA-C12a
0-XMA-C12a was synthesized with a yield of 64% according to the general
procedure for the glycosylation of Example 2-4. 11-1 NMR (400MHz, CDC13): 6
8.02-7.96 (m, 27H), 7.93-7.91 (m, 4H), 7.89-7.86 (m, 8H), 7.83-7.77 (m, 81-1),
7.76-
7.74 (m, 8H), 7.67 (t, J = 7.2 Hz, 2H), 7.59 (t, J = 7.2 Hz, 2H), 7.54-7.24
(m, 81H),
7.13-7.11 (m, 2H), 6.54-6.52 (m, 2H), 6.18-6.11 (m, 4H), 5.75-5.63 (m, 8H),
5.37-
5.30 (m, 4H), 5.26-5.20 (m, 4H), 5.17-5.13 (m, 4H), 4.66-4.15 (m, 32H), 3.39
(d, J =
.. 8.8 Hz, 2H), 3.21 (d, J = 8.8 Hz, 2H), 2.87 (d, J = 8.8 Hz, 2H), 2.75 (d, J
= 8.8 Hz,
21-1), 2.24 (d, J = 8.8 Hz, 2H), 2.22 (d, J = 8.8 Hz, 2H), 1.27-1.07 (m,
4414), 0.88 (t, J
= 7.2 Hz, 6H); 13C NMR (100MHz, CDC13): 6 166.2, 166.1, 166.0, 165.9, 165.7,
165.6, 165.3, 165.2, 164.9, 136.3, 133.9, 133.7, 133.6, 133.4, 133.3, 130.1,
129.9,
129.8, 129.6, 129.4, 129.2, 129.1, 129.0, 128.9, 128.8, 128.7, 128.6, 128.5,
128.4,
100.9, 96.1, 95.6, 74.8, 72.2, 72.0, 71.9, 71.6, 71.4, 69.9, 96.2, 69.1, 62.8,
62.7, 42.4,
32.1, 31.6, 30.8, 30.1, 30.0, 29.9, 29.8, 29.6, 23.7, 22.9, 14.3.
<15-5> Synthesis of 0-XMA-C12
0-XMA-C12 was synthesized with a yield of 93% according to the general
procedure for the deprotection of Example 2-5. FIG. 28 shows the 11-1 NMR
spectrum, and FIG. 29 shows the 13C NMR spectrum. Ill NMR (400 MHz,
CD30D): 6 7.26-7.24 (m, 2H), 7.09-7.07 (m, 2H), 5.20-5.16 (m, 4H), 4.41-4.37
(m,
4H), 3.92-3.81 (m, 14H), 3.73-3.52 (m, 28H), 3.47-3.36 (m, 16H), 3.33-3.24 (m,
6H),
3,00 (d, J = 13.2 Hz, 2H), 2.76 (d, J 13.2 Hz, 2H), 1.34-1.21 (m, 44H), 0.90
(t, J =
7.2Hz, 6H); 13C NMR (100 MHz, CD30D): 6 139.3, 132.9, 126.6, 105.0, 104.9,
61

CA 02997394 2018-03-02
103.1, 81.7, 78.1, 76.6, 75.2, 75.0, 74.9, 74.3, 71.6, 62.9, 62.5, 44.4, 33.3,
32.9, 31.9,
31.0, 30.9, 30.7, 24.4, 23.9, 14.7; HRMS (El): calcd. for C86F1150044 [M+Nar
1909.9398, found 1909.9406.
<Preparation Example 16> Synthesis of 0-XMA-C14
<16-1> Synthesis of diethyl 2-tetradecylmalonate (3)
Diethyl 2-tetradecylmalonate (3) was synthesized with a yield of 90%
according to the general procedure for the synthesis of Compound A of Example
2-1.
IFINMR (400 MHz, CDC13): 6 4.22-4.16 (m, 4H), 3.31 (t, J = 7.6 Hz, I H), 1.90-
1.87
(m, 2H), 1.30-1.25 (m, 30H), 0.87 (t, J = 7.2 Hz, 311); 13C NMR (100 MHz,
CDCI3):
6 169.9, 61.5, 52.3, 32.1, 29.9, 29.7, 29.6, 29.5, 29.4, 28.9, 27.5, 22.9,
14.4.
<16-2> Synthesis of tetraethyl 2,2'-(1,2-phenylenebis(methylene))bis(2-
tetradecylmalonate) (8")
Tetraethyl 2,2'-(l,2-pheny lenebis(methylene))bis(2-
tetradecylmalonate)
(8") was synthesized with a yield of 79% by introducing an o-xylene linker
according to the general procedure for the introduction of a xylene linker of
Example
2-2. Ili NMR (400 MHz, CDC13): 6 7.10-7.08 (m, 2H), 7.06-7.03 (m, 2H), 4.21-
4.06 (m, 8H). 3.27 (s, 4H), 1.76-1.74 (m, 4H), 1.31-1.18 (m, 60H), 0.89 (t, J
= 7.2Hz,
6H); '3C NMR (100 MHz, CDC13): 6 171.7, 135.9, 126.8, 61.3, 59.2, 33.9, 32.4,
32.1,
30.0, 29.9, 29.8, 29.6, 22.9, 14.4, 14.2.
<16-3> Synthesis of 2,2'-(1,2-phenylenebis(methylene))bis(2-
tetradecylpropane-1,3-diol) (13")
2,2' -(1,2-pheny lenebis(methy lene))bis(2-tetradecylpropane-1,3-diol) (13")
was synthesized with a yield of 84% according to the general procedure for the
reduction of an ester using LAH of Example 2-3. ill NMR (400 MHz, CDC13): 6
62

CA 02997394 2018-03-02
7.22-7.21 (m, 2H), 7.15-7.12 (m, 2H), 3.59-3.52 (m, 8H), 2.84 (s, 4H), 1.43-
1.24 (m,
52H), 0.88 (t, J = 7.2Hz, 6H); 13C NMR (100 MHz, CDC13): 5 138.5, 124.7,
124.6,
66.8, 39.1, 35.9, 31.9, 31.3, 30.2, 29.6, 29.3, 25.3, 22.7, 14.1.
<16-4> Synthesis of 0-XMA-C14a
O-XMA-C I4a was synthesized with a yield of 65% according to the general
procedure for the glycosylation of Example 2-4. 1H NMR (400MHz, CDC13): 8
8.02-7.96 (m, 27H), 7.93-7.91 (m, 4H), 7.89-7.86 (in, 8H), 7.83-7.77 (m, 8H),
7.76-
7.74 (m, 8H), 7.67 (t, J = 7.2 Hz, 2H), 7.59 (t, J = 7.2 Hz, 2H), 7.54-7.24
(m, 81H),
7.13-7.11 (m, 2H), 6.54-6.52 (m, 2H), 6.18-6.11 (m, 4H), 5.75-5.63 (m, 8H),
5.37-
5.30 (m, 4H), 5.26-5.20 (m, 4H), 5.17-5.13 (m, 4H), 4.66-4.15 (m, 32H), 3.39
(d, J =
8.8 Hz, 2H), 3.21 (d, J = 8.8 Hz, 2H), 2.87 (d, J --= 8.8 Hz, 2H), 2.75 (d, J
= 8.8 Hz,
2H), 2.24 (d, J = 8.8 Hz, 2H), 2.22 (d, J 8.8 Hz, 2H), 1.27-1.07(m, 52H), 0.88
(t,J
= 7.2 Hz, 6H) ; 13C NMR (100MHz, CDC13): 8 166.2, 166.1, 166.0, 165.9, 165.7,
165.6, 165.3, 165.2, 164.9, 136.3, 133.9, 133.7, 133.6, 133.4, 133.3, 130.1,
129.9,
129.8, 129.6, 129.4, 129.2, 129.1, 129.0, 128.9, 128.8, 128.7, 128.6, 128.5,
128.4,
100.9, 96.1, 95.6, 74.8, 72.2, 72.0, 71.9, 71.6, 71.4, 69.9, 96.2, 69.1, 62.8,
62.7, 42.4,
32.1, 31.6, 30.8, 30.1, 30.0, 29.9, 29.8, 29.6, 23.7, 22.9, 14.3.
<16-5> Synthesis of 0-XMA-C14
0-XMA-C14 was synthesized with a yield of 92% according to the general
procedure for the deprotection of Example 2-5. FIG. 30 shows the 1H NMR
spectrum, and FIG. 31 shows the 13C NMR spectrum. 1H NMR (400MHz,
CD30D): 8 7.26-7.24 (m, 2H), 7.09-7.07 (m, 2H), 5.20-5.16 (m, 4H), 4.41-4.37
(m,
4H), 3.92-3.81 (m, 14H), 3.73-3.52 (m, 28H), 3.47-3.36 (m, 16H), 3.33-3.24 (m,
6H),
3.00 (d, J = 13.2 Hz, 2H), 2.76 (d, J = 13.2 Hz, 2H), 1.34-1.21 (m, 52H), 0.90
(t, J =
63

CA 02997394 2018-03-02
7.2Hz, 6H); 13C NMR (100 MHz, CD30D): 8 139.4, 126.6, 105.0, 104.9, 103.1,
81.7,
78.1, 76.7, 75.2, 75.0, 74.9, 74.3, 71.6, 62.9, 62.5, 44.4, 33.3, 31.9, 31.0,
30.9, 30.7,
24.4, 23.9, 14.7; HRMS (El): calcd. for C9014158044 [M+Na] 1967.0058, found
1967.0082.
<Preparation Example 17> Synthesis of 0-XMA-C16
<17-1> Synthesis of diethyl 2-hexadecylmalonate (4)
Diethyl 2-hexadecylmalonate (4) was synthesized with a yield of 86%
according to the general procedure for the synthesis of Compound A of Example
2-1.
NMR (400 MHz, CDC13): 8 4.23-4.16 (m, 4H), 3.31 (t, J = 7.6 Hz, 1H), 1.90-1.87
(m, 2H), 1.30-1.25 (m, 34H), 0.87 (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz,
CDC13):
8 169.9, 61.5, 52.3, 32.1, 29.9, 29.7, 29.6, 29.5, 29.4, 28.9, 27.5, 27.2,
22.9, 14.4.
<17-2> Synthesis of tetraethyl 2,2'-(1,2-phenylenebis(methylene))bis(2-
hexadecylmalonate) (9")
Tetraethyl 2,2' -(1,2-pheny lenebis(methylene))bis(2-
hexadecylmalonate)
(9") was synthesized with a yield of 75% by introducing an o-xylene linker
according to the general procedure for the introduction of a xylene linker of
Example
2-2. 114 NMR (400 MHz, CDC13): 8 7.10-7.07 (m, 2H), 7.05-7.03 (m, 2H), 4.19-
4.08 (m, 8H), 3.27 (s, 4H), 1.76-1.74 (m, 4H), 1.27-1.20 (m, 68H), 0.88 (t, J
= 7.2Hz,
6H); '3C NMR (100 MHz, CDC13): 8 171.7, 135.9, 126.8, 61.3, 59.2, 33.9, 32.1,
30.0,
29.9, 29.8, 29.6, 24.6, 22.9, 14.4, 14.2.
<17-3> Synthesis of 2,2'-(1,2-phenylenebis(methylene))bis(2-
hexadecylpropane-1,3-diol) (14")
2,2' -(1,2-phenylenebi s(methy lene))bis(2-hexadecy Ipropane-1,3-diol) (14")
was synthesized with a yield of 80% according to the general procedure for the
64

CA 02997394 2018-03-02
reduction of an ester using LAH of Example 2-3. IFI NMR (400 MHz, CDCI3):
7.22-7.21 (m, 2H), 7.15-7.12 (m, 2H), 3.59-3.52 (m, 8H), 2.84 (s, 4H), 1.43-
1.24 (m,
60H), 0.88 (t, J = 7.2Hz, 6H); 13C NMR (100 MHz, CDCI3): 6 138.5, 124.7,
124.6,
66.8, 39.1, 35.8, 31.9, 31.2, 30.2, 29.6, 29.4, 25.2, 22.7, 14.1.
<17-4> Synthesis of 0-XIVIA-C16a
0-XMA-C16a was synthesized with a yield of 61% according to the general
procedure for the glycosylation of Example 2-4. 111 NMR (400 MHz, CDCI3):
8.02-7.96 (m, 271-1), 7.93-7.91 (m, 4H), 7.89-7.86 (m, 8H), 7.83-7.77 (m, 8H),
7.76-
7.74 (m, 8H), 7.67 (t, J = 7.2 Hz, 2H), 7.59 (t, J = 7.2 Hz, 21-1), 7.54-7.24
(m, 81H),
7.13-7.11 (m, 2H), 6.54-6.52 (m, 214), 6.18-6.11 (m, 4H), 5.75-5.63 (m, 8H),
5.37-
5.30 (m, 4H), 5.26-5.20 (m, 411), 5.17-5.13 (m, 411), 4.66-4.15 (m, 321-1),
3.39 (d, J =
8.8 Hz, 211), 3..21 (d, J = 8.8 Hz, 211), 2.87 (d, J = 8.8 Hz, 2H), 2.75 (d, J
= 8.8 Hz,
211), 2.24 (d, J = 8.8 Hz, 2H), 2.22 (d, J 8.8 Hz, 2H), 1.27-1.07 (m, 60H),
0.88 (t, J
= 7.2 Hz, 6H); 13C NMR (100MHz, CDCI3): 6 166.2, 166.1, 166.0, 165.9, 165.7,
165.6, 165.3, 165.2, 164.9, 136.3, 133.9, 133.7, 133.6, 133.4, 133.3, 130.1,
129.9,
129.8, 129.6, 129.4, 129.2, 129.1, 129.0, 128.9, 128.8, 128.7, 128.6, 128.5,
128.4,
100.9, 96.1, 95.6, 74.8, 72.2, 72.0, 71.9, 71.6, 71.4, 69.9, 96.2, 69.1, 62.8,
62.7, 42.4,
32.1, 31.6, 30.8, 30.1, 30.0, 29.9, 29.8, 29.6, 23.7, 22.9, 14.3.
<17-5> Synthesis of 0-XMA-C16
0-XMA-C16 was synthesized with a yield of 94% according to the general
procedure for the deprotection of Example 2-5. FIG. 32 shows the 114 NMR
spectrum, and FIG. 33 shows the 13C NMR spectrum. IFI NMR (400MHz,
CD30D): 6 7.26-7.24 (m, 2H), 7.09-7.07 (m, 2H), 5.20-5.16 (m, 4H), 4.41-4.37
(m,
4H), 3.92-3.81 (m, I4H), 3.73-3.52 (m, 2814). 3.47-3.36 (m, 1611), 3.33-3.24
(m, 6H),

CA 02997394 2018-03-02
3.00 (d, J = 13.2 Hz, 2H), 2.76 (d, J = 13.2 Hz, 2H), 1.34-1.21 (m, 52H), 0.90
(t, J =
7.2Hz, 6H); I3C NMR (100 MHz, CD30D): 8 139.3, 132.9, 105.0, 104.9, 103.1,
81.7,
78.1, 76.6, 75.2, 74.9, 74.3, 71.6, 62.9, 62.6, 44.4, 34.9, 33.3, 31.9, 31.0,
30.9, 30.7,
24.4, 23.9, 14.7; HRMS (El): calcd. for C9414166044 [M+Nar- 2023.0684, found
2022.0647.
<Preparation Example 18> Synthesis of 0-XMA-C18
<18-1> Synthesis of diethyl 2-octadecylmalonate (5)
Diethyl 2-octadecylmalonate (5) was synthesized with a yield of 88%
according to the general procedure for the synthesis of Compound A of Example
2-1.
11-1 NMR (400 MHz, CDC13): 8 4.23-4.16 (m, 4H), 3.31 (t, J = 7.6 Hz, 1H), 1.90-
1.87
(m, 2H), 1.30-1.25 (m, 38H), 0.87 (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz,
CDC13):
169.9, 61.5, 52.3, 32.1, 29.9, 29.8, 29.7, 29.6, 29.5, 29.4, 28.9, 27.5, 27.2,
22.9,
14.4.
<18-2> Synthesis of tetraethyl 2,2'-(1,2-phenylenebis(methylene))bis(2-
octadecylmalonate) (10")
Tetraethyl 2,2' -(1,2-
phenylenebis(methy I ene))bis(2-octadecylmalonate)
(10") was synthesized with a yield of 71% by introducing an o-xylene linker
according to the general procedure for the introduction of a xylene linker of
Example
2-2. 1H NMR (400 MHz, CDCI3): 8 7.10-7.07 (m, 2H), 7.05-7.03 (m, 2H), 4.19-
4.08 (m, 8H), 3.27(s, 4H), 1.76-1.74 (m, 4H), 1.27-1.20 (m, 76H), 0.88 (t, J =
7.2Hz,
6H); 13C NMR (100 MHz, CDC13): 8 171.7, 135.9, 126.8, 61.3, 59.2, 33.9, 32.1,
30.0,
29.9, 29.8, 29.7, 29.6, 24.6, 22.9, 14.2.
<18-3> Synthesis of 2,2'-(1,2-
phenylenebis(methylene))bis(2-
octadecylpropane-1,3-diol) (15")
66

CA 02997394 2018-03-02
2,2' -(1,2-phenylenebis(methylene))bis(2-octadecylpropane-1,3-diol) (15")
was synthesized with a yield of 77% according to the general procedure for the
reduction of an ester using LAH of Example 2-3. ill NMR (400 MHz, CDC13): 6
7.22-7.21 (m, 21-1), 7.15-7.12 (m, 2H), 3.59-3.52 (m, 8H), 2.84 (s, 4H), 1.43-
1.24 (m,
68H), 0.88 (t, J = 7.2Hz, 6H); NMR (100 MHz, CDCI3): 6 138.5, 124.7, 124.6,
66.8, 39.2, 35.9, 31.9, 31.2, 30.2, 29.6, 29.3, 25.2, 22.7, 14.1.
<18-4> Synthesis of 0-XMA-C18a
0-XMA-C18a was synthesized with a yield of 62% according to the general
procedure for the glycosylation of Example 2-4. NMR (400MHz,
CDCI3): 6
8.02-7.96 (m, 27H), 7.93-7.91 (m, 4H), 7.89-7.86 (m, 8H), 7.83-7.77 (m, 8H),
7.76-
7.74 (m, 8H), 7.67 (t, J ¨ 7.2 Hz, 2H), 7.59 (t, J ¨ 7.2 Hz, 2H), 7.54-7.24
(m, 81H),
7.13-7.11 (m, 2H), 6.54-6.52 (m, 2H), 6.18-6.11 (m, 4H), 5.75-5.63 (m, 8H),
5.37-
5.30 (m, 4H), 5.26-5.20 (m, 4H), 5.17-5.13 (m, 4H), 4.66-4.15 (m, 32H), 3.39
(d, J =
8.8 Hz, 2H), 3..21 (d, J = 8.8 Hz, 211), 2.87 (d, J = 8.8 Hz, 211), 2.75 (d, J
= 8.8 Hz,
.. 2H), 2.24 (d, J = 8.8 Hz, 2H), 2.22 (d, J = 8.8 I lz, 2H), 1.27-1.07 (m,
68H), 0.88 (t,
= 7.2 Hz, 61-1); "C NMR (400MHz, CDCI3): 6 166.2, 166.1, 166.0, 165.9, 165.7,
165.6, 165.3, 165.2, 164.9, 136.3, 133.9, 133.7, 133.6, 133.4, 133.3, 130.1,
129.9,
129.8, 129.6, 129.4, 129.2, 129.1, 129.0, 128.9, 128.8, 128.7, 128.6, 128.5,
128.4,
100.9, 96.1, 95.6, 74.8, 72.2, 72.0, 71.9, 71.6, 71.4, 69.9, 96.2, 69.1, 62.8,
62.7, 42.4,
32.1, 31.6, 30.8, 30.1, 30.0, 29.9, 29.8, 29.6, 23.7, 22.9, 14.3.
<18-5> Synthesis of 0-XMA-C18
0-XMA-C18 was synthesized with a yield of 91% according to the general
procedure for the deprotection of Example 2-5. FIG. 34 shows the 1H NMR
spectrum, and FIG. 35 shows the "C NMR spectrum. 11-1 NMR (400MHz, CD3OD
67

CA 02997394 2018-03-02
+ 1 % (CD3)2S0): 6 7.27-7.25 (m, 2H), 7.09-7.07 (m, 2H), 5.19-5.16 (m, 4H),
4.40-
4.37 (m, 4H), 3.91-3.81 (m, 14H), 3.72-3.51 (m, 28H), 3.46-3.34 (m, 16H), 3.30-
3.23
(m, 6H), 2.98 (d, J = 13.2 Hz, 2H), 2.75 (d, J = 13.2 Hz, 2H), 1.34-1.23 (m,
52H),
0.90 (t, J = 7.2Hz, 6H); 13C NMR (100 MHz, CD30D): 6 139.3, 132.9, 105.0,
104.9,
103.0, 81.6, 78.1, 76.7, 75.2, 75.0, 74.9, 74.3, 73.2, 71.6, 62.8, 62.5, 44.4,
33.2, 31.9,
31.0, 30.9, 30.6, 23.9, 14.7; HRMS (El): calcd. for C9814174044 [M+Na]+
2079.1310,
found 2079.1541.
<Example 3> Characteristics of XMAs
To confirm the characteristics of P-XMAs of Preparation Examples 1 to 5
synthesized according to the synthesis method of Example 1, and M-XMAs and 0-
XMAs of Preparation Examples 9 to 18 synthesized according to the synthesis
method of Example 2, molecular weights (M.W.) of XMAs, a critical micellar
concentration (CMC) and hydrodynamic radii (Rh) of the formed micelles were
measured.
Specifically, the critical micellar concentration (CMC) was measured using
fluorescence staining and diphenylhexatriene (DPH), and the hydrodynamic radii
(Rh) of the micelles formed by agents were measured through a dynamic light
scattering (DLS) experiment. The measured results are shown in Tables 1 and 2,
compared with a conventional amphiphilic molecule (detergent), DDM.
[Table 11
Detergent M.W. CMC ( M) CMC (wt%) Rh (nm)
P-XMA-C8 1775.9 ¨20 ¨0.004 2.7 0.04
P-XMA-C9 1803.9 ¨10 ¨0.002 3.2 1 0.01
68

CA 02997394 2018-03-02
P-XMA-C10 1832.0 -7 -0.001 3.5 0.01
P-XMA-Cll 1860.0 -3 -0.0006 3.3 0.03
P-XMA-C12 1888.1 -1 -0.0002 3.7 0.01
DDM 510.1 -170 -0.0087 3.4 0.02
[Table 21
Detergent M.W. CMC (04) CMC (wt%) Rh (nm)
P-XMA-C 1 1 1860.0 -3.0 -0.0006 3.3 1 0.03
M-XMA-C11 1860.0 -6.0 -0.0011 3.2 0.01
0-XMA-C11 1860.0 -10 -0.0019 3.0 0.02
M-XMA-C12 1888.1 -4.0 -0.0008 3.4 0.02
O-XMA-C 12 1888.1 -6.0 -0.0011 3.2 0.03
M-XMA-C14 1994.2 -2.5 -0.0005 3.6 0.07
O-XMA-C 14 1994.2 -3.0 -0.0006 3.5 0.04
M-XMA-C16 2000.3 -2.0 -0.0004 3.9 1 0.04
0-XMA-C 16 2000.3 -2.0 -0.0004 3.9 0.06
M-XMA-C18 2056.4 -1.5 -0.0003 4.1 0.04
0-XMA-C18 2056.4 -1.5 -0.0003 3.9 1 0.04
DDM 510.1 -170 -0.0087 3.4 0.02
The CMC values of XMAs were 1 to 20 p,M, which were smaller than that of
DDM (170 M). In addition, as the alkyl chain length of a compound was
increased, the CMC value became smaller. Among P-XMAs, P-XMA-C8, which
has the shortest alkyl chain, had a CMC value of approximately 20 [tM (-0.004
wt%),
and P-XMA-C12, which has the longest alkyl chain, had a CMC value of 1 M
(-0.0002 wt%). The CMC values of M-XMAs and 0-XMAs tended to be reduced
69

CA 02997394 2018-03-02
as the alkyl chain lengths thereof were increased. Specifically, 0-XMA-C11
having the shortest alkyl chain had the highest CMC value of approximately 10
RM,
and 0-XMA-C18 having the longest alkyl chain had the smallest CMC value of
approximately 1.5 M. In comparison between isomers, the CMC values of 0-
XMAs were a little higher than those of M-XMAs. Therefore, micelles were
easily
formed even with a small amount of XMAs, confirming that XMAs have higher
solubility than DDM.
Sizes of the micelles formed by P-XMAs tended to increase according to the
length of an alkyl chain. That is, the smallest micelle was P-XMA-C8 (2.7 nm),
and the largest micelle was P-XMA-C12 (3.7 nm). In terms of the micelle size,
P-
XMA-C8 and P-XMA-C9 were smaller than DDM, and P-XMA-C10 and P-XMA-
C11 were similar to DDM. In addition, M-/O-XMAs having a longer alkyl chain
formed larger micelles, which corresponded to the experimental result for P-
XMAs
according to the change in alkyl chain length. In comparison between isomers,
M-
XMAs tended to form larger micelles than 0-XMAs.
Therefore, M-XMAs had smaller CMC values and formed larger micelles
than 0-XMAs. P-XMAs tended to have smaller CMC values, and form larger
micelles. It was considered that differences in CMC value (that is,
agglomerating
tendency) and micelle size between the isomeric XMAs were associated with the
difference in efficiency of an amphiphilic compound with respect to a target
membrane protein. Compared to DDM, all XMAs had smaller CMC values than
DDM, and the micelle sizes of XMAs were larger or smaller than that of DDM
according to the alkyl chain length.

CA 02997394 2018-03-02
Meanwhile, the results of measuring the size distribution of XMA micelles
are shown in FIGS. 36 and 37. P-XMA-C8 and P-XMA-C9 showed one set of
micelles like DDM, and P-XMA-C10, P-XMA-Cll and P-XMA-C12 had two sets of
micelles having different radii (FIG. 36). The number (%) of the two sets of
micelles was estimated to be 106 or more, which is based on the fact that
dynamic
light scattering is proportional to the sixth power of the micelle radius.
Therefore, a
set of micelles having a smaller radius is an exclusive entity present in an
amphiphilic solution containing P-XMA-C10, P-XMA-C 1 1 or P-XMA-C12. In
addition, M-XMAs and 0-XMAs showed a single set of micelles in terms of a
size,
.. indicating high micelle uniformity (FIG. 37).
From such a result, since XMAs of the present invention had smaller CMC
values than DDM and thus easily form micelles even with a small amount, it can
be
confirmed that they had a much higher self-assembly tendency than DDM, similar
sizes of micelles formed by XMAs to DDM, and were similar to the conventional
DDM in terms of a geometrical structure of a molecule.
<Example 4> Evaluation of ability to stabilize structure of membrane
protein (Borl) of compound according to the present invention
An experiment for measuring the structural stability of a boron transporter
(Borl) in an aqueous solution due to P-XMAs was performed. The Borl structural
stability was measured using a CPM assay, and concentrations of P-XMAs and DDM
were estimated by measuring relative amounts of folded proteins at CMC + 0.04
wt% (a) and CMC + 0.2 wt% (b) to analyze Borl protein stability according to
the
concentration of an amphiphilic molecule.
71

CA 02997394 2018-03-02
Specifically, Borl was expressed as a fusion protein with a C-terminal GFP-
His tag in S. cerevisiae. All steps were carried out at 4 C. A Borl-
containing
membrane was resuspended with PBS (pH 7.4), 100 mM NaC1, and 10% glycerol
and solubilized in 1% DDM for 1 hour with gentle stirring, followed by
ultracentrifugation at 200,000 g for 45 minutes. The supernatant was adjusted
with
mM imidazole, and applied to two 5 ml Ni2'-NTA columns pre-equilibrated with
Buffer A (PBS (pH 7.4), 100 mM NaCl, 10% glycerol, 0.03% DDM) supplemented
with 10 mM imidazole. The column was washed with 5 CV of Buffer A
supplemented with 30 mM imidazole, and washed with 5 CV of Buffer A
10 supplemented with 50 mM imidazole, followed by elution in Buffer A
supplemented
with 500 mM imidazole. Fractions containing Borl-GFP were diluted (1:10) in
Buffer B (20 mM Tris (pH 7.5), 150 m1VI NaCl, 0.03% DDM) supplemented with
10% glycerol, and incubated overnight with an equi-molar concentration of His-
tagged TEV protease to cleave the GFP-His tag. The sample was applied to a 5
ml
Ni2+-NTA column pre-equilibrated with Buffer B supplemented with 20 mM
imidazole to separate Borl from the GFP-His tag and TEV. The flow-through
containing Borl was concentrated to 0.5 ml using a centrifugal concentrator.
The
protein was subjected to gel filtration purification using a Superdex 200
10/300
column pre-equilibrated with Buffer B. Borl was concentrated to 7 mg/ml using
a
centrifugal concentrator. 4 mg/ml of N44-(7-
diethylamino)-4-methy1-3-
coumarinyl]phenyl)maleimide (CPM dye; Invitrogen) stored in DMSO (Sigma) was
diluted in an assay buffer (20 mM Tris (pH 7.5), 150 mM NaCl) supplemented
with
0.03% DDM. 150 I of an assay buffer supplemented with CMC + 0.04 wt% or
CMC + 0.20 wt% of P-XMAs or DDM was loaded into a Nunc 96-well clear bottom
72

CA 02997394 2018-03-02
plate. 1 I of Borl (7 mg/ml) was added to each well before adding 3 I of a
diluted CPM dye. A clear plate cover was added, and the fluorescence of each
well
was monitored at 40 C for 120 minutes.
As shown in FIG. 38, Borl solubilized in DDM after two hours of the
incubation at 40 C showed the most instable state, but an amount of structure-
denatured protein was relatively small in each P-XMA solution and exhibited a
Borl
protein stabilization effect. In addition, at concentrations of CMC+0.04 wt%
and
CMC+0.2 wt%, all P-XMAs had higher Borl stabilization ability than DDM, and
all
P-XMAs stabilized the protein at similar levels.
From such a result, it can be seen that P-XMAs had a higher ability to
stabilize the Borl structure than conventional DDM.
<Example 5>. Evaluation of ability to stabilize membrane protein (LeuT)
structure of compound according to the present invention
An experiment for measuring the structural stability of a LeuT protein due to
M-XMAs or 0-XMAs was performed. Each amphiphilic compound was used at
CMC + 0.04 wt% (a) or CMC + 0.2 wt% (b), and the ligand-binding activity of
LeuT
was determined using [3H]-Leu by scintillation proximity assay (SPA).
Measurement was regularly performed at room temperature during a 12-day
incubation period.
Specifically, wild-type leucine transporter (LeuT) derived from thermophilic
bacteria Aquzlex aeolicus was purified according to a previously disclosed
protocol
(G. Deckert et al., Nature 1998, 392, 353-358). In summary, LeuT was expressed
in E. coli C41 (DE3) incubated in lysogeny broth supplemented with 0.1 mg/ml
ampicillin. Protein
expression was induced by adding isopropyl 13-D-
73

CA 02997394 2018-03-02
thiogalactopyranoside at the final concentration of 0.1 mM. Cell membranes
were
isolated from disrupted cells (Constant Systems Homogenizers, Kennesaw, GA),
and
solubilized in 1% (w/v) n-dodecy1-13-D-maltopyranoside (DDM; Affymetrix, Santa
Clara, CA). After solubilization, LeuT was fixed to a chelating Sepharose Fast
Flow resin (GE Healthcare), and approximately 90 to 100% pure LeuT was eluted
in
20 mM Tris-HC1 (pH 7.5), 199 mM KCI, 1mM NaCI, 0.05%(w/v) DDM and 300
mM imidazole. Afterward, the purified LeuT (approximately 1.2 mg mL-1) was
diluted 10 times with buffer which is the same as that used above and
supplemented
with M-XMAs and O-XMA, except DDM and imidazole, at the final concentration
of CMC + 0.04% (w/v) or CMC + 0.2% (w/v). DDM and P-XMA-CI I were used
as positive controls. Protein samples were stored at room temperature, and
protein
activity at a predetermined time was determined by measuring [3HReucine
binding
using SPA. SPA was performed using a total volume of 100 [IL of 51.11_, of
each
protein sample solubilized in a buffer containing 450 mM NaC1, 50 nM [311]-
Leucine
and 0.125 mg ml` copper chelate (His-Tag) YSi beads (Perkin Elmer, Denmark).
A [31-1]-Leucine binding degree was measured using a MicroBeta liquid
scintillation
counter (Perkin Elmer).
As a result, M-XMA-C12 and 0-XMA-C12 showed substantial
reinforcement of long-term stability of LeuT, compared with DDM. M-XMA-C12
showed higher stability than 0-XMA-C12. However, as the alkyl chain lengths of
XMAs were further increased from Cl2 to C18, the ligand binding activity of
LeuT
was reduced, and therefore it can be seen that, when the XMA has a C12 alkyl
chain
length, it was most preferable for the LeuT protein. Even when a concentration
of
the amphiphilic compound was increased to CMC + 0.2 wt%, a similar tendency
was
74

CA 02997394 2018-03-02
observed. XMAs (M-XMA-C12 and 0-XMA-C12) with the C12 alkyl chain were
superior at maintaining the ligand binding activity of LeuT compared to DDM,
and
M-XMA-C12 had generally better performance than 0-XMA-C12 (FIG. 39).
As a result, it can be confirmed that M-XMA-C12 and 0-XMA-C12
.. exhibited improved efficiency in maintaining the ligand binding affinity of
LeuT,
compared to DDM, and thus were excellent in stabilization of the LeuT protein.
<Example 6> Evaluation of ability to stabilize structure of membrane
protein (MelB) of compound according to the present invention
An experiment for measuring the structural stability of the Salmonella
typhimurium melibiose permease (MelB) protein due to XMAs was performed.
The MelB protein was extracted on a membrane using XMAs and DDM, and the
amount and structure of the extracted protein were analyzed by SDS-PAGE and
western blotting. A concentration of the used compound was 1.5 wt%, and the
protein was extracted at a different temperature (0, 45, 55, or 65 C) to
evaluate two
kinds of performance such as protein extraction efficiency and stabilization
ability of
the compound at the same time. Membrane samples that were not treated with
XMAs or DDM were used as controls.
Specifically, MelBst stability due to DDM and XMAs was evaluated
according to the method described in the paper (P. S. Chae, et al., Nat.
Methods 2010,
.. 7, 1003-1008.) written by the inventor in 2010. The protein (MelBst) was
produced
using plasmid pK95AAHB/WT MelBst/CH10 encoding wild-type MelB with a 10-
His tag at the C-terminus and Salmonella typhimurium DW2 cells (AmelB and
AlacZY). Cell growth and membrane preparation were carried out according to
the
method described in the paper (Nat. Commun. 2014, 5, 3009) written by A. S.

CA 02997394 2018-03-02
Ethayathulla et al. A protein assay was performed using a Micro BCA kit
(Thermo
Scientific, Rockford, IL). To measure solubilization/stability, MelBst-
containing
membrane samples (final protein concentration of 10 mg/mL) were incubated with
a
solubilization buffer (20 mM sodium phosphate, pH 7.5, 200 mM NaC1, 10%
glycerol, 20 mM melibiose) and 1.5% (w/v) DDM, P-XMAs (P-XMA-C8, P-XMA-
C9, P-XMA-C10, P-XMA-C11 and P-XMA-C12), M-XMAs (M-XMA-C11, M-
XMA-C12, M-XMA-C14, M-XMA-C16 and M-XMA-C18) or 0-XMAs (0-XMA-
C11, 0-XMA-C12, 0-XMA-C14, 0-XMA-C16 and 0-XMA-C18) at four different
temperatures (0, 45, 55 and 65 C) for 90 minutes. Following
ultracentrifugation at
355,590g in a Beckman OptimaTM MAX ultracentrifuge using a TLA-100 rotor for
45 minutes at 4 C, 20 lug proteins were separated by SDS-16% PAGE, and then
immunoblotted with a Penta-His-HRP antibody (Qiagen, Germantown, MD).
MelBst was detected using a SuperSignal West Pico chemiluminescent substrate
by
an ImageQuant LAS 4000 Biomolecular Imager (GE Health Care Life Sciences).
As shown in FIG. 40, DDM showed high protein extraction efficiency at 0
and 45 C, but proteins solubilized at 55 C or more were hardly observed.
This
means that, as a temperature of MelBq extracted by DDM was increased, the
protein
was denatured or agglomerated and thus disappeared. However, P-XMA-C9, P-
XMA-C10 and P-XMA-C12 had increased protein extraction efficiency at 45 C and
55 C, exhibited extraction efficiency at the same level as DDM at 45 C, and
had a
higher MelBst extraction ability than DDM at 55 C. In addition, at 65 C,
while
DDM did not extract the protein, P-XMA-C10 and P-XMA-C12 extracted Me1130.
Such a result shows that P-XMA-C9, P-XMA-C10 and P-XMA-C12 exhibited a
higher MelBst stabilization ability than DDM.
76

CA 02997394 2018-03-02
In addition, as shown in FIG. 41 and FIG. 42, at 0 C, M-XMAs (e.g., M-
XMA-C16 and M-XMA-C18) having a longer alkyl chain showed protein extraction
efficiency at almost the same level as DDM. However, M-XMAs and 0-XMAs
showed protein extraction efficiency at a higher or similar level compared to
P-
XMA-C11. M-XMAs and 0-XMAs exhibited different tendencies with respect to
the alkyl chain length of a hydrophobic group of the amphiphilic compound.
MelB
solubilization efficiency tended to increase according to an increase in the
alkyl
chain length of M-XMAs, but tended to decrease according to an increase in the
alkyl chain length of 0-XMAs. When the temperature was increased to 45 C,
overall tendencies were similar to those at 0 C. In addition, a
solubilization yield
tended to increase according to an increase in the alkyl chain length of M-
XMAs, but
tended to decrease according to an increase in the alkyl chain length of 0-
XMAs.
When the temperature was increased to 55 C, DDM was failed to maintain the
solubilization of MelB, and this is because the proteins solubilized with DDM
at a
high temperature were agglomerated or denatured. However, except M-XMA-C18
and 0-XMA-C18, all M-XMAs and 0-XMAs had the ability to maintain MelB
solubilization. Among M-XMAs, M-XMA-C14 was most effective, and retained
approximately 70%-solubilized MelB. Since the ability of M-XMA-C14 to ensure
MelB solubility was not greatly changed according to a temperature change, the
compound can be seen to be effective in the solubilization and stabilization
of a
membrane protein.
From such a result, it can be confirmed that XMAs of the present invention
had a higher MelB protein stabilization ability than DDM, and MelB protein
extraction efficiency, which is the same at 45 C and higher at 55 C compared
to
77

CA 02997394 2018-03-02
DDM. Particularly, in terms of stabilization of the MelB protein, it can be
seen that
M-XMA-Cl2 and 0-XMA-C11¨C14 had the optimum alkyl chain lengths.
<Example 6> Evaluation of ability to stabilize structure of membrane
protein (132AR) of compound according to the present invention
An experiment for measuring the structural stability of a human 132
adrenergic receptor (132AR) and a G protein-coupled receptor (GPCR) due to
XMAs
was carried out.
<6-1> Measurement of mBBr-P2AR solubilized in micelles formed by
XMAs and DDM according to absence or presence of full agonist (ISO) and
combination of G-protein
An experiment for measuring the structural change and stability of mBBr-
132AR due to P-XMA-C11 and DDM according to the absence or presence of a full
agonist (ISO) and a combination of ISO and a G-protein was carried out.
Specifically, (32AR solubilized in 0.1% DDM was purified according to the
method described in the paper (Science 2007, 318, 1266-1273.) written by D. M.
Rosenbaum et al., and concentrated to approximately 1 mg/ml. 0.5 ul of
unliganded
and BI (agonist)-binding monobromobimane (mBB)-labeled 112AR, which was
solubilized in 0.1% DDM at 50 p.M, was diluted with 500 ul of a 0.04+CMC % P-
XMA-C11 or P-XMA-C12 buffer (finally, 50 nM receptor). The receptor was
incubated for 30 minutes, and the mBBr spectrum was measured, compared to the
spectrum of mBB-labeled receptor in 0.1% DDM. mBBr-132AR fluorescence was
measured at 370 nm, and emission from 430 to 510 nm was measured using a Spex
FluoroMax-3 spectrofluorometer (Jobin Yvon Inc.) at 1-nm units with 1 nm s-1,
and
78

CA 02997394 2018-03-02
the photon counting mode was set at 4-nm emission bandwidth pass. The mBBR
solubilized in DDM was used as a positive control.
Meanwhile, a G protein coupling assay was carried out by the following
method. Monobromobimane (mBBr)-labeled 132AR (mainly at Cys265) was used to
measure changes in fluorescence affected by local conformational changes near
transmembrane helix 6 (TM6). Such measurement was performed by the method
suggested by S. E. Mansoor et al. (Biochemistry 2002, 41, 2475-2484.). 0.5 sl
of
50 AM unliganded mBBr-labeled receptor was diluted with 500 1.11 of a 20xCMC P-
XMA-Cll or P-XMA-C12 buffer (finally 50 nM receptor) for 10 minutes at RT. In
addition, 2 M isopreoterenol (ISO) was added, and the resulting product was
incubated for another 10 minutes. After 250 nM Gs was further added, the
resulting
product was incubated at RT for 15 minutes, and mBB-132AR fluorescence was
measured.
As shown in FIG. 43a, when the full agonist ISO was present, the bimane
spectrum of the receptor in P-XMA-Cll or P-XMA-C12 was similar to that of the
receptor in DDM. In addition, the bimane spectrum of the receptor/G-protein
complex solubilized in P-XMA-C I I was similar to that of the complex
solubilized in
DDM. In addition, the receptor solubilized in P-XMA-C12 also showed a similar
tendency thereto (FIG. 44).
Such a result shows that P-XMA-C 1 1 and P-XMA-C12 function well in
receptor activation by G-protein coupling. Such a decrease in fluorescence
intensity and change in maximum emission wavelength mean conformational
changes from inactive to active states, generated by the binding of ISO and a
G-
79

CA 02997394 2018-03-02
protein, indicating that the structure of ft2AR solubilized in P-XMA-C II or P-
XMA-
C12 behaves in a manner similar to receptors present in the cell membrane.
<6-2> Measurement of mBBr-P2AR at CMC or less
An experiment for comparing changes in protein structures of XMAs and
DDM at CMC or less of an amphiphilic molecule was carried out.
Specifically, 0.5 I of an unliganded mBB-labeled receptor solubilized in 20
x CMC P-XMA-C 1 1 or P-XMA-C12 at 50 M was diluted with 500 I of a NH
buffer (20 mM HEPES pH 7.5, 100 mM NaC1). The protein was incubated for 30
minutes, and the mBBr spectrum was measured. The receptor solubilized in 0.1%
DDM was diluted with a NH buffer, and used as a control.
As shown in FIG. 43h, (32AR solubilized in DDM showed a clear structural
change due to dilution, but the receptor solubilized in P-XMA-C11 or P-XMA-C12
showed less structural change.
From such a result, it can be confirmed that P-XMA-Cll or P-XMA-C12
has excellent structural stability of the 132AR protein at CMC or less,
compared to
DDM, which means that a rate of separating the amphiphilic molecules from
receptors under a condition of CMC or less is low.
<6-3> Measurement of ligand (DHA) binding activity of mBBr-p2AR
using radioligand binding assay
An activation degree of a receptor (mBBr-(32AR) purified by DDM or XMAs
was measured by [3H]-dihydroalprenolol ([3f1]-DHA) binding.
Specifically, a radioligand binding assay was performed by the following
method. 132AR was purified in the presence of 0.1% DDM. After p2AR was
reloaded into an MI Flag column in the presence of 2 mM CaCl2, a DDM (0.1%)-

CA 02997394 2018-03-02
XMA (0.2%) buffer mixture was prepared in a ratio of 50:50, 20:80, 10:90, 5:95
or
0:100. The receptor was eluted in 20xCMC XMA with 5 mM EDTA and 0.2
mg/ml of a free Flag peptide. 0.1 pmol purified I32AR solubilized in DDM, P-
XMA-
C11, P-XMA-C12, M-XMAs or 0-XMAs was incubated with 10 nM of radioactive
DI-LA [3H]-dihydroalprenolol (DHA) for 30 minutes at room temperature. The
mixture was loaded into a G-50 column, and a flow-through was collected with a
binding buffer (20 mM HEPES pH 7.5, supplemented with 0.5 mg/ml BSA, 100 mM
NaC1), and further filled with 15 ml of a scintillation fluid. Receptor-
binding
[3Fl]DHA was measured with a scintillation counter (Beckman). Non-specific
binding of [31-1]-DHA was calculated by adding 1 IIM of alprenolol (Sigma) in
the
same binding reaction. The binding degree of [31-1]-DHA was measured as a
column graph.
As shown in FIG. 43c, the receptor purified by P-XMA-C11 or P-XMA-C12
had a radioactive-ligand binding degree similar to the receptor purified by
DDM.
This means that the activity of the receptor is well maintained while
amphiphilic
molecules of XMAs are replaced with DDM molecules surrounding the receptor.
In addition, as shown in FIG. 45, M-XMA-C 1 I had a higher radioactive-
ligand binding degree than P-XMA-C 11. When the alkyl chain length of the
amphiphilic molecule was increased from C11 to C12, the effect of the
amphiphilic
molecule was further increased. In maintaining the ligand binding activity of
the
receptor, M-XMA-C12 was superior to 0-XMA-C12, and similar to DDM. As the
alkyl chain length of M-XMAs was increased to C18, the effect of the
amphiphilic
compound was reduced. That is, in M-XMAs, it can be seen that the C12 alkyl
chain
length was optimal for maintaining the activity of the receptor, which
corresponded
81

CA 02997394 2018-03-02
to the result for LeuT. 0-XMAs had a difference from M-XMAs, and less change
in the effect of maintaining the activity of the receptor according to the
change in
alkyl chain length. It is expected that different tendencies in the effects of
M-
XMAs and 0-XMAs according to the alkyl chain length are caused by different
effects on binding to a target membrane protein due to different geometrical
structures.
From such a result, it was seen that P-XMA-Cl 1, P-XMA-C12, M-XMA-
C11, M-XMA-C12 and 0-XMAs can be used as alternatives for DDM, which is
most widely used in 132AR studies.
By using xylene-based compounds according to exemplary embodiments of
the present invention, compared to a conventional compound, a membrane protein
can be stably stored in an aqueous solution for a long time, and can be
subjected to
functional analysis and structural analysis.
Since the structural and functional analysis of a membrane protein is one of
the fields of highest interest in biology and chemistry, the compounds
according to
exemplary embodiments of the present invention can be applied in research on
protein structure that is closely related to development of a new drug.
Specifically, the compounds according to exemplary embodiments of the
present invention can form a high quality membrane protein crystal due to a
small
size when a complex with the membrane protein is formed, and have a xylene
linker
which is structurally rigid and two quaternary carbon atoms introduced at a
xylene
terminal, thereby greatly limiting the flowability of the total molecule, and
therefore
the crystallization of the membrane protein can be promoted.
82

CA 02997394 2018-03-02
In addition, since the compounds of the present invention can be synthesized
from a starting material that can be easily obtained by a simple method, the
compounds can be mass-produced for research on a membrane protein.
It will be apparent to those skilled in the art that various modifications can
be
made to the above-described exemplary embodiments of the present invention
without departing from the spirit or scope of the invention. Thus, it is
intended that
the present invention covers all such modifications provided they come within
the
scope of the appended claims and their equivalents.
83

Dessin représentatif
Une figure unique qui représente un dessin illustrant l'invention.
États administratifs

2024-08-01 : Dans le cadre de la transition vers les Brevets de nouvelle génération (BNG), la base de données sur les brevets canadiens (BDBC) contient désormais un Historique d'événement plus détaillé, qui reproduit le Journal des événements de notre nouvelle solution interne.

Veuillez noter que les événements débutant par « Inactive : » se réfèrent à des événements qui ne sont plus utilisés dans notre nouvelle solution interne.

Pour une meilleure compréhension de l'état de la demande ou brevet qui figure sur cette page, la rubrique Mise en garde , et les descriptions de Brevet , Historique d'événement , Taxes périodiques et Historique des paiements devraient être consultées.

Historique d'événement

Description Date
Représentant commun nommé 2020-11-07
Inactive : COVID 19 - Délai prolongé 2020-03-29
Accordé par délivrance 2020-03-24
Inactive : Page couverture publiée 2020-03-23
Inactive : Taxe finale reçue 2020-02-05
Préoctroi 2020-02-05
Un avis d'acceptation est envoyé 2019-12-18
Lettre envoyée 2019-12-18
month 2019-12-18
Un avis d'acceptation est envoyé 2019-12-18
Représentant commun nommé 2019-10-30
Représentant commun nommé 2019-10-30
Inactive : Q2 réussi 2019-10-17
Inactive : Approuvée aux fins d'acceptation (AFA) 2019-10-17
Modification reçue - modification volontaire 2019-08-07
Inactive : Dem. de l'examinateur par.30(2) Règles 2019-02-13
Inactive : Rapport - Aucun CQ 2019-02-08
Inactive : Page couverture publiée 2018-05-23
Inactive : CIB en 1re position 2018-05-14
Inactive : Acc. récept. de l'entrée phase nat. - RE 2018-03-20
Inactive : CIB attribuée 2018-03-15
Inactive : CIB attribuée 2018-03-15
Inactive : CIB attribuée 2018-03-15
Demande reçue - PCT 2018-03-15
Inactive : CIB attribuée 2018-03-15
Lettre envoyée 2018-03-15
Inactive : CIB attribuée 2018-03-15
Inactive : CIB attribuée 2018-03-15
Exigences pour l'entrée dans la phase nationale - jugée conforme 2018-03-02
Exigences pour une requête d'examen - jugée conforme 2018-03-02
Toutes les exigences pour l'examen - jugée conforme 2018-03-02
Demande publiée (accessible au public) 2017-03-09

Historique d'abandonnement

Il n'y a pas d'historique d'abandonnement

Taxes périodiques

Le dernier paiement a été reçu le 2019-04-12

Avis : Si le paiement en totalité n'a pas été reçu au plus tard à la date indiquée, une taxe supplémentaire peut être imposée, soit une des taxes suivantes :

  • taxe de rétablissement ;
  • taxe pour paiement en souffrance ; ou
  • taxe additionnelle pour le renversement d'une péremption réputée.

Les taxes sur les brevets sont ajustées au 1er janvier de chaque année. Les montants ci-dessus sont les montants actuels s'ils sont reçus au plus tard le 31 décembre de l'année en cours.
Veuillez vous référer à la page web des taxes sur les brevets de l'OPIC pour voir tous les montants actuels des taxes.

Historique des taxes

Type de taxes Anniversaire Échéance Date payée
TM (demande, 2e anniv.) - générale 02 2018-04-16 2018-03-02
Taxe nationale de base - générale 2018-03-02
Requête d'examen - générale 2018-03-02
TM (demande, 3e anniv.) - générale 03 2019-04-15 2019-04-12
Taxe finale - générale 2020-04-20 2020-02-05
Pages excédentaires (taxe finale) 2020-04-20 2020-02-05
TM (brevet, 4e anniv.) - générale 2020-04-15 2020-04-08
TM (brevet, 5e anniv.) - générale 2021-04-15 2021-03-26
TM (brevet, 6e anniv.) - générale 2022-04-19 2022-03-29
TM (brevet, 7e anniv.) - générale 2023-04-17 2023-03-24
TM (brevet, 8e anniv.) - générale 2024-04-15 2024-04-05
Titulaires au dossier

Les titulaires actuels et antérieures au dossier sont affichés en ordre alphabétique.

Titulaires actuels au dossier
INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS
Titulaires antérieures au dossier
KYUNG HO CHO
PIL SEOK CHAE
Les propriétaires antérieurs qui ne figurent pas dans la liste des « Propriétaires au dossier » apparaîtront dans d'autres documents au dossier.
Documents

Pour visionner les fichiers sélectionnés, entrer le code reCAPTCHA :



Pour visualiser une image, cliquer sur un lien dans la colonne description du document (Temporairement non-disponible). Pour télécharger l'image (les images), cliquer l'une ou plusieurs cases à cocher dans la première colonne et ensuite cliquer sur le bouton "Télécharger sélection en format PDF (archive Zip)" ou le bouton "Télécharger sélection (en un fichier PDF fusionné)".

Liste des documents de brevet publiés et non publiés sur la BDBC .

Si vous avez des difficultés à accéder au contenu, veuillez communiquer avec le Centre de services à la clientèle au 1-866-997-1936, ou envoyer un courriel au Centre de service à la clientèle de l'OPIC.

 Télécharger sélection en format PDF (archive Zip)
 Télécharger sélection (en un fichier PDF fusionné)
Description du
Document 		 Date
(yyyy-mm-dd) 		 Nombre de pages   Taille de l'image (Ko) 
Description 2018-03-01 83 2 445
Dessins 2018-03-01 46 2 358
Abrégé 2018-03-01 1 15
Revendications 2018-03-01 13 187
Dessin représentatif 2018-03-01 1 103
Page couverture 2018-05-22 1 79
Description 2019-08-06 83 2 488
Revendications 2019-08-06 13 185
Abrégé 2019-08-06 1 22
Dessin représentatif 2020-03-03 1 5
Page couverture 2020-03-03 1 40
Paiement de taxe périodique 2024-04-04 2 43
Accusé de réception de la requête d'examen 2018-03-14 1 175
Avis d'entree dans la phase nationale 2018-03-19 1 203
Avis du commissaire - Demande jugée acceptable 2019-12-17 1 503
Rapport de recherche internationale 2018-03-01 6 276
Traité de coopération en matière de brevets (PCT) 2018-03-01 4 134
Modification - Abrégé 2018-03-01 2 100
Demande d'entrée en phase nationale 2018-03-01 4 157
Déclaration 2018-03-01 2 32
Demande de l'examinateur 2019-02-12 4 230
Paiement de taxe périodique 2019-04-11 1 26
Modification / réponse à un rapport 2019-08-06 11 200
Taxe finale 2020-02-04 4 126